Dafna D. Gladman

Dafna D. Gladman's AcademicInfluence.com Rankings

Dafna D. Gladman

Biology

#1464

World Rank

#2454

Historical Rank

Immunology

#73

World Rank

#79

Historical Rank

biology Degrees

Dafna D. Gladman

Philosophy

#2094

World Rank

#3655

Historical Rank

Logic

#466

World Rank

#876

Historical Rank

philosophy Degrees

Download Badge

Biology
Philosophy

Why Is Dafna D. Gladman Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Dafna D. Gladman, MD, FRCPC, is a Canadian doctor and medical researcher working in the fields of psoriatic arthritis, systemic lupus erythematosus, and rheumatoid arthritis. She is a professor at the University of Toronto Faculty of Medicine and Senior Scientist at the Krembil Research Institute. She is Deputy Director, Centre for Prognosis Studies in the Rheumatic Diseases , Co-Director, Lupus Clinic, Toronto Western Hospital and Director, Psoriatic Arthritis Program, Toronto Western Hospital.

(See a Problem?)

Dafna D. Gladman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. (1992) (4493)
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. (2011) (3649)
Classification criteria for psoriatic arthritis: development of new criteria from a large international study. (2006) (2873)
Systemic lupus erythematosus disease activity index 2000. (2002) (2430)
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. (1996) (2101)
Psoriatic arthritis: epidemiology, clinical features, course, and outcome (2005) (1340)
Methods for assessing responsiveness: a critical review and recommendations. (2000) (1294)
Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways (2008) (1070)
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus (2019) (936)
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. (2005) (864)
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility (2011) (807)
Treatment recommendations for psoriatic arthritis (2008) (796)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis (2016) (764)
Psoriatic arthritis (PSA)--an analysis of 220 patients. (1987) (694)
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. (1997) (691)
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci (2013) (689)
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). (2005) (642)
Mortality in systemic lupus erythematosus. (1987) (584)
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. (2009) (582)
Epidemiology of psoriatic arthritis in the population of the United States. (2005) (570)
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity (2012) (555)
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force (2017) (476)
Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. (2008) (450)
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. (2000) (440)
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. (2008) (429)
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus (2019) (419)
Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. (2003) (398)
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor (2014) (398)
Identification of fifteen new psoriasis susceptibility loci highlights the role of innate immunity (2012) (397)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 (2016) (396)
Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. (1995) (396)
Psoriatic Arthritis. (2017) (391)
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort (2014) (377)
An international cohort study of cancer in systemic lupus erythematosus. (2005) (372)
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. (2004) (372)
Cutting Edge: Susceptibility to Psoriatic Arthritis: Influence of Activating Killer Ig-Like Receptor Genes in the Absence of Specific HLA-C Alleles1 (2002) (362)
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. (2013) (358)
Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. (1997) (343)
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2 (2010) (343)
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials (2012) (340)
Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. (2001) (338)
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors (2017) (330)
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. (2012) (325)
Genome-wide association analysis identifies three psoriasis susceptibility loci (2010) (314)
Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. (1998) (312)
Changing Patterns in Mortality and Disease Outcomes for Patients with Systemic Lupus Erythematosus (2008) (301)
The frequency and outcome of lupus nephritis: results from an international inception cohort study. (2016) (301)
HLA antigens in psoriatic arthritis. (1986) (296)
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. (2007) (295)
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. (2011) (294)
Consensus on a core set of domains for psoriatic arthritis. (2007) (289)
Cardiovascular morbidity in psoriatic arthritis (2008) (286)
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. (2007) (285)
Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. (1997) (284)
Accrual of organ damage over time in patients with systemic lupus erythematosus. (2003) (282)
Cutting Edge: Heterozygote Advantage in Autoimmune Disease: Hierarchy of Protection/Susceptibility Conferred by HLA and Killer Ig-Like Receptor Combinations in Psoriatic Arthritis1 (2004) (279)
Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. (1999) (279)
Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. (1995) (276)
Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta‐analysis of observational and clinical studies (2019) (275)
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) (2008) (265)
Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus (2001) (264)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus‐Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis (2018) (255)
The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. (2010) (254)
Transancestral mapping and genetic load in systemic lupus erythematosus (2017) (253)
Lupus and pregnancy studies. (1993) (253)
Longitudinal study of clinical and radiological progression in psoriatic arthritis. (1990) (249)
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project) (2012) (246)
Cancer risk in systemic lupus: an updated international multi-centre cohort study. (2013) (242)
Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. (2015) (240)
Dactylitis in psoriatic arthritis: a marker for disease severity? (2004) (239)
Mortality in systemic lupus erythematosus: the bimodal pattern revisited. (1985) (238)
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus (2009) (236)
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year (2006) (227)
The nature and outcome of infection in systemic lupus erythematosus (2002) (226)
Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis (2011) (222)
Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants (2016) (219)
Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. (1997) (215)
Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1 (2015) (214)
Morbidity in systemic lupus erythematosus. (1987) (213)
Association of Variants at 1q32 and STAT3 with Ankylosing Spondylitis Suggests Genetic Overlap with Crohn's Disease (2010) (209)
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis (2018) (207)
Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. (1995) (203)
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. (2007) (203)
The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. (1999) (201)
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. (2012) (195)
Assessment of patients with psoriatic arthritis: a review of currently available measures. (2004) (194)
Psoriatic arthritis assessment tools in clinical trials (2005) (194)
Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? (2011) (194)
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis (2018) (192)
Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes (2014) (190)
Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS) (2008) (190)
Association of interleukin-23 receptor variants with ankylosing spondylitis. (2008) (189)
Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. (1991) (188)
Premature atherosclerosis in systemic lupus erythematosus. (2000) (188)
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial (2006) (187)
Depression and Anxiety in Psoriatic Disease: Prevalence and Associated Factors (2014) (185)
Vitamin D insufficiency in a large female SLE cohort (2010) (184)
Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. (1994) (183)
The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study (2016) (182)
Outcome measures to be used in clinical trials in systemic lupus erythematosus. (1999) (182)
Functional Assessment of Chronic Illness Therapy-Fatigue Scale is valid in patients with psoriatic arthritis (2007) (177)
Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. (2012) (177)
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. (2008) (177)
Malignancy in systemic lupus erythematosus. (1996) (177)
CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. (2003) (176)
International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials (2016) (175)
Lupus retinopathy. Patterns, associations, and prognosis. (1988) (173)
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). (2008) (171)
Familial aggregation of psoriatic arthritis (2008) (170)
Fatigue in lupus is not correlated with disease activity. (1998) (168)
Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci (2015) (167)
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus (2010) (167)
The lupus activity criteria count (LACC). (1984) (165)
TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis (2011) (164)
A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. (1993) (162)
Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. (2006) (161)
Psoriatic arthritis imaging: a review of scoring methods (2005) (161)
Accurately describing changes in disease activity in Systemic Lupus Erythematosus. (2000) (160)
Predictors for radiological damage in psoriatic arthritis: results from a single centre (2006) (156)
Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. (2010) (156)
Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases (2015) (156)
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (2017) (156)
Aberrations in lymphocyte subpopulations and function during psychological stress. (1982) (156)
Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. (2007) (155)
Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. (1979) (154)
Longterm followup of childhood lupus nephritis. (2002) (153)
The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case–cohort study (2007) (151)
Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. (1998) (150)
Natural history of hypercholesterolemia in systemic lupus erythematosus. (1999) (149)
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials (2016) (149)
Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. (1992) (148)
Lack of association between the interferon-α signature and longitudinal changes in disease activity in systemic lupus erythematosus (2008) (148)
Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. (2007) (147)
The challenge of indication extrapolation for infliximab biosimilars. (2014) (146)
Radiological assessment in psoriatic arthritis. (1998) (145)
Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. (2003) (145)
Natural history of psoriatic arthritis. (1994) (142)
Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus (2011) (138)
Quality of life over time in patients with systemic lupus erythematosus. (2008) (137)
Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. (2000) (137)
Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. (2000) (136)
Fibromyalgia is a major contributor to quality of life in lupus. (1997) (136)
Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial (2019) (136)
Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis (2013) (136)
Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis (2011) (136)
Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis (2007) (135)
The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. (2004) (135)
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort (2012) (135)
Systemic Lupus Erythematosus in Males (1983) (134)
Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. (1995) (134)
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. (2007) (133)
Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study (2012) (132)
Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus. (1992) (131)
The effect of pregnancy on lupus nephritis. (2004) (130)
Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. (2010) (129)
Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. (2005) (129)
Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. (2012) (129)
Association between the interleukin-1 family gene cluster and psoriatic arthritis. (2006) (128)
Peripheral neuropathy in patients with systemic lupus erythematosus. (2011) (127)
Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis (2011) (126)
Endpoints: consensus recommendations from OMERACT IV (2000) (126)
Factors associated with fatigue in patients with systemic lupus erythematosus (1999) (124)
Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. (2011) (124)
Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. (1999) (123)
Non-Hodgkin’s lymphoma in systemic lupus erythematosus (2005) (123)
Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort (2010) (122)
Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison (2018) (122)
Psoriatic arthritis and imaging (2005) (121)
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial (2018) (120)
The Effect of Lupus Nephritis on Pregnancy Outcome and Fetal and Maternal Complications (2010) (120)
Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis. (1992) (120)
Genome-wide meta-analysis of Psoriatic Arthritis Identifies Susceptibility Locus at REL (2011) (120)
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. (2008) (120)
Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. (2009) (118)
Prolonged remission in systemic lupus erythematosus. (2005) (118)
Association of a specific ERAP1/ARTS1 haplotype with disease susceptibility in ankylosing spondylitis. (2009) (118)
Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis (2015) (117)
Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and Outcome (2010) (117)
Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. (2001) (117)
Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (2006) (115)
Genetics of psoriasis and psoriatic arthritis: update and future direction. (2008) (114)
Psoriatic spondyloarthropathy: a long term prospective study. (1988) (113)
Axial disease in psoriatic arthritis (2007) (113)
Pregnancy outcome following first trimester exposure to chloroquine. (1991) (113)
Remission in psoriatic arthritis. (2001) (112)
The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. (1995) (112)
Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort. (2012) (112)
Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus (2007) (112)
Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. (1995) (111)
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort (2012) (111)
Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study) (2014) (111)
The 1000 Canadian Faces of Lupus: Determinants of Disease Outcome in a Large Multiethnic Cohort (2009) (110)
Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT Study (2011) (110)
The rate and pattern of organ damage in late onset systemic lupus erythematosus. (2002) (108)
Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. (1994) (108)
Mycophenolate Mofetil for Induction Treatment of Lupus Nephritis: A Systematic Review and Metaanalysis (2011) (107)
Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. (1996) (106)
The Early Protective Effect of Hydroxychloroquine on the Risk of Cumulative Damage in Patients with Systemic Lupus Erythematosus (2013) (106)
Clinical Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort: Incidence, Prevalence, Characteristics, and Outcome (2017) (106)
Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. (1999) (106)
Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. (2000) (105)
Lymphoma risk in systemic lupus: effects of disease activity versus treatment (2012) (105)
Mortality in psoriatic arthritis. (2008) (105)
Validity assessment of the disabilities of arm, shoulder, and hand questionnaire (DASH) for patients with psoriatic arthritis. (1999) (104)
Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials (2013) (104)
Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity (2011) (103)
Anti-C1q antibodies in systemic lupus erythematosus (2015) (103)
Pulmonary hypertension in systemic lupus (2004) (103)
Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity (2012) (102)
Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. (2001) (102)
A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients. (2002) (102)
International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. (2009) (102)
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. (2008) (102)
Lupus pregnancy. A prospective study of placental changes. (1988) (101)
Clinical predictors of fetal outcome in systemic lupus erythematosus. (1998) (101)
Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares. (1994) (100)
Improved survival in psoriatic arthritis with calendar time. (2007) (99)
Mechanisms of copy number variation and hybrid gene formation in the KIR immune gene complex (2009) (99)
Incidence of arthritis in a prospective cohort of psoriasis patients (2011) (99)
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. (2007) (99)
Axial Psoriatic Arthritis: Update on a Longterm Prospective Study (2009) (98)
An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA (2010) (97)
Occurrence and correlates of fatigue in psoriatic arthritis (2008) (97)
Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. (2008) (95)
The liver in systemic lupus erythematosus. (1984) (94)
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study (2012) (94)
Risk Factors for Axial Inflammatory Arthritis in Patients with Psoriatic Arthritis (2010) (94)
Progression in psoriatic arthritis: role of time varying clinical indicators. (1999) (93)
Genome-wide scan reveals association of psoriasis with IL-23 and NFB pathways (2016) (93)
Excessive paternal transmission in psoriatic arthritis. (1999) (92)
Fatigue in systemic lupus erythematosus: contributions of disordered sleep, sleepiness, and depression. (2006) (92)
Development and Initial Validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50 (2011) (91)
HLA markers and progression in psoriatic arthritis. (1998) (91)
Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT (2010) (91)
The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada. (2004) (91)
A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time? (2007) (91)
Psoriatic arthritis. (2004) (91)
Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. (2008) (90)
Fibromyalgia in human immunodeficiency virus infection. (1990) (89)
Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis (2005) (89)
Premature atherosclerosis in systemic lupus erythematosus. (2005) (89)
Association of Interleukin 23 Receptor Variants with Psoriatic Arthritis (2008) (89)
Prolonged Clinical Remission in Patients with Systemic Lupus Erythematosus (2014) (89)
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1) (2017) (89)
Clinical Features and Diagnostic Considerations in Psoriatic Arthritis. (2015) (89)
The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease (2013) (89)
A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE) (1996) (88)
Prevalence of malignancy in psoriatic arthritis. (2008) (88)
HLA-C locus alleles in patients with psoriatic arthritis (PsA). (1999) (88)
The SLICC/ACR damage index: progress report and experience in the field (1999) (87)
Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2014) (87)
Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort (2007) (87)
Dilemmas in neuropsychiatric lupus. (1993) (87)
SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation (2011) (86)
ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients (2015) (86)
Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016 (2017) (86)
Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. (1996) (86)
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. (2013) (84)
Clinical and radiological damage in psoriatic arthritis (2005) (84)
Incidence and predictors for cardiovascular events in patients with psoriatic arthritis (2015) (83)
Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. (1995) (83)
Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. (1993) (83)
Is the Madrid Sonographic Enthesitis Index Useful for Differentiating Psoriatic Arthritis from Psoriasis Alone and Healthy Controls? (2014) (82)
Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. (2006) (82)
Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. (2000) (81)
The Development of Psoriatic Arthritis in Patients With Psoriasis Is Preceded by a Period of Nonspecific Musculoskeletal Symptoms: A Prospective Cohort Study (2016) (80)
A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. (1995) (80)
Dactylitis in Psoriatic Arthritis: Prevalence and Response to Therapy in the Biologic Era (2013) (80)
Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients (2004) (80)
Incremental Effects of Comorbidity on Quality of Life in Patients with Psoriatic Arthritis (2013) (79)
Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. (2006) (78)
The association between smoking and the development of psoriatic arthritis among psoriasis patients (2011) (78)
Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. (1998) (78)
Mortality related to cerebrovascular disease in systemic lupus erythematosus (2006) (78)
TNFα polymorphisms and risk of psoriatic arthritis (2005) (78)
Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis (2014) (78)
The use of sulfasalazine in psoriatic arthritis: a clinic experience. (1998) (78)
Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments (2017) (77)
Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis (2014) (77)
Antihomocitrullinated Fibrinogen Antibodies are Specific to Rheumatoid Arthritis and Frequently Bind Citrullinated Proteins/peptides (2014) (77)
Pattern of neuropsychologic dysfunction in inactive systemic lupus erythematosus. (1997) (76)
Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period (2012) (76)
A family study of the antiphospholipid syndrome associated with other autoimmune diseases. (1992) (75)
Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study (2011) (75)
Dyslipidemia in systemic lupus erythematosus: just another comorbidity? (2016) (75)
Prolactin in systemic lupus erythematosus. (1994) (74)
Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density (2004) (74)
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study (2016) (74)
Risk Factors for Development of Coronary Artery Disease in Women with Systemic Lupus Erythematosus (2009) (74)
Quality of life in systemic lupus erythematosus patients during more and less active disease states: differential contributors to mental and physical health. (1999) (74)
Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis (2014) (73)
Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients (2018) (73)
SLEDAI-2K for a 30-day window (2010) (73)
Clinical aspects of the spondyloarthropathies. (1998) (73)
Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis (2012) (73)
Pathologic features of diabetic thick skin. (1987) (73)
Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. (1998) (72)
Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis? (2020) (72)
Venous syndromes and pulmonary embolism in systemic lupus erythematosus. (1980) (72)
Reliability of measurements of active and damaged joints in psoriatic arthritis. (1990) (72)
Expanded Population of Activated Antigen-Engaged Cells within the Naive B Cell Compartment of Patients with Systemic Lupus Erythematosus1 (2008) (71)
The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone (2012) (71)
Living with lupus: a prospective pan-Canadian study. (2001) (71)
Predictors of response to intra-articular steroid injection in psoriatic arthritis. (2010) (70)
Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. (2005) (70)
Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. (2003) (70)
Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. (2008) (70)
Defining Low Disease Activity in Systemic Lupus Erythematosus (2017) (69)
Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. (2001) (69)
How to improve morbidity and mortality in systemic lupus erythematosus. (2000) (69)
All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971–2013) (2019) (69)
Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? (2010) (69)
Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort (2014) (69)
Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment (2014) (68)
Epigenetics of psoriatic disease: A systematic review and critical appraisal. (2017) (67)
Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort (2019) (67)
Prognosis and treatment of systemic lupus erythematosus (1995) (67)
HLA is a candidate region for psoriatic arthritis. evidence for excessive HLA sharing in sibling pairs. (2003) (66)
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments (2021) (66)
Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database (2018) (65)
Serial renal biopsy in systemic lupus erythematosus. (2000) (65)
Current concepts in psoriatic arthritis. (2002) (65)
Responses to Adalimumab in Patients with Active Psoriatic Arthritis Who Have Not Adequately Responded to Prior Therapy: Effectiveness and Safety Results From an Open-label Study (2010) (65)
Factors Explaining the Discrepancy Between Physician and Patient Global Assessment of Joint and Skin Disease Activity in Psoriatic Arthritis Patients (2015) (65)
Is There an Advantage Over SF-36 with a Quality of Life Measure That Is Specific to Systemic Lupus Erythematosus? (2011) (65)
IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients (2011) (65)
Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review (2016) (64)
Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study (2014) (64)
Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence. (2000) (64)
Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. (2005) (64)
Brief Report: CXCL10 Is a Possible Biomarker for the Development of Psoriatic Arthritis Among Patients With Psoriasis (2016) (63)
Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials (2014) (63)
Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. (2013) (63)
Kidney biopsy in systemic lupus erythematosus (1994) (63)
Chloroquine therapy in psoriatic arthritis. (1992) (63)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 (2022) (63)
Systemic lupus erythematosus and pregnancy. (1980) (63)
HLA markers for susceptibility and expression in scleroderma. (2005) (63)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 (2022) (63)
25‐Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort (2014) (63)
Hormone replacement therapy in systemic lupus erythematosus. (1997) (63)
The use of single photon emission computerized tomography in neuropsychiatric SLE: a pilot study. (1995) (62)
Kidney biopsy in SLE. I. A clinical-morphologic evaluation. (1989) (62)
Vascular events in hypertensive patients with systemic lupus erythematosus (2000) (62)
Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. (2006) (62)
Psoriatic arthritis: recent advances in pathogenesis and treatment. (1992) (61)
Contributions of observational cohort studies in systemic lupus erythematosus: the university of toronto lupus clinic experience. (2005) (61)
Counterbalancing patient demands with evidence: Results from a pan-canadian randomized clinical trial of brief supportive-expressive group psychotherapy for women with systemic lupus erythematosus (2002) (61)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015 (2015) (61)
Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus (2016) (61)
Kidney biopsy in systemic lupus erythematosus. II. Survival analyses according to biopsy results. (1991) (60)
Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. (2011) (60)
Group psychotherapy reduces illness intrusiveness in systemic lupus erythematosus. (2003) (60)
The "shrinking lungs syndrome" in systemic lupus erythematosus--improvement with corticosteroid therapy. (1992) (60)
Treatment guidelines in psoriatic arthritis (2020) (59)
Malakoplakia and immunosuppressive therapy. Reversal of clinical and leukocyte abnormalities after withdrawal of prednisone and azathioprine. (1985) (59)
Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. (2013) (58)
Psoriatic spondyloarthropathy in men and women: a clinical, radiographic, and HLA study. (1992) (58)
Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review. (2000) (58)
Systemic lupus erythematosus with negative LE cells and antinuclear factor. (1978) (58)
Clinical and radiological changes during psoriatic arthritis disease progression. (2003) (57)
Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. (2006) (56)
Impaired brachial artery endothelium dependent flow mediated dilation in systemic lupus erythematosus: preliminary observations (2004) (55)
Hyperuricemia in Psoriatic Arthritis Prevalence and Associated Features (2000) (55)
Folate Pathway Enzyme Gene Polymorphisms and the Efficacy and Toxicity of Methotrexate in Psoriatic Arthritis (2010) (55)
The association between sonographic enthesitis and radiographic damage in psoriatic arthritis (2017) (55)
Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort (2016) (55)
Accelerated atheroma in lupus—background (2000) (54)
A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles (2011) (54)
Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. (2014) (53)
Clinically active serologically quiescent systemic lupus erythematosus. (2003) (53)
Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis (2013) (53)
Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2) (2015) (53)
Diagnosis and Management of Psoriatic Arthritis (2012) (53)
Longitudinal study of the bidirectional association between pain and depressive symptoms in patients with psoriatic arthritis (2012) (52)
Lung cancer in systemic lupus erythematosus. (2007) (52)
Measures of disease activity and damage in SLE. (1998) (51)
Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus. (2000) (51)
Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. (2014) (51)
Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria (2009) (51)
SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus (2011) (51)
The significance of thrombocytopenia in systemic lupus erythematosus. (1983) (51)
Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab (2012) (50)
Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases? (2006) (50)
Atherosclerosis in psoriatic disease: latest evidence and clinical implications (2015) (49)
Musculoskeletal manifestations of infection with human immunodeficiency virus. (1990) (49)
Soluble Biomarkers Associated with Response to Treatment with Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis (2013) (49)
Race/ethnicity and cancer occurrence in systemic lupus erythematosus. (2005) (49)
Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Population‐Based Study (2019) (49)
HLA alleles in systemic sclerosis: association with pulmonary hypertension and outcome. (1992) (49)
Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. (2006) (49)
Psoriatic arthritis (2019) (49)
A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. (2017) (48)
Evaluation of predictive factors for neurocognitive dysfunction in patients with inactive systemic lupus erythematosus. (2000) (48)
A Conditional Markov Model for Clustered Progressive Multistate Processes under Incomplete Observation (2004) (47)
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis (2019) (47)
Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort (2015) (47)
The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients (2007) (47)
Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study (2017) (47)
Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. (2003) (47)
Posterior reversible encephalopathy syndrome: an emerging disease manifestation in systemic lupus erythematosus. (2011) (46)
Juvenile psoriatic arthritis and HLA antigens. (1990) (46)
Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study (2017) (46)
Psoriatic arthritis screening tools. (2008) (46)
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure (2015) (46)
The effect of menopause on disease activity in systemic lupus erythematosus. (2006) (46)
Changes in Quality of Life in the First 5 Years of Disease in a Multicenter Cohort of Patients With Systemic Lupus Erythematosus (2014) (46)
Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. (2012) (45)
Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease (2018) (45)
Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors (2018) (45)
Antimalarial-induced cardiomyopathy: a systematic review of the literature (2018) (45)
Minimal Disease Activity and Anti–Tumor Necrosis Factor Therapy in Psoriatic Arthritis (2015) (45)
Psoriatic Arthritis from Wright’s Era Until Today (2009) (45)
Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2018) (45)
Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis (2010) (44)
Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria (2018) (44)
INCREASED FREQUENCY OF HLA-DRW2 IN SLE (1979) (44)
The Canadian Rheumatology Association/ Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project. (2007) (44)
Patient-Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (2013) (44)
Peripheral vascular disease in patients with systemic lupus erythematosus. (1992) (44)
Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. (2008) (43)
Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2005) (43)
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1 (2020) (43)
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond (2019) (43)
Autoantibodies in biological agent naive patients with psoriatic arthritis (2005) (43)
The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients (2017) (43)
Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand? (2013) (43)
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (2019) (43)
Myocardial Perfusion Imaging in Assessing Risk of Coronary Events in Patients with Systemic Lupus Erythematosus (2009) (43)
Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity (2008) (43)
2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations (2015) (42)
The Juvenile Psoriatic Arthritis Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes (2017) (42)
Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus (2017) (42)
Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus (2006) (42)
HLA-D region genes and rheumatoid arthritis (RA): importance of DR and DQ genes in conferring susceptibility to RA. (1992) (41)
Outcome measures in psoriatic arthritis. (2007) (41)
Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design (2009) (41)
Update on Biomarkers in Psoriatic Arthritis (2010) (41)
TNFalpha polymorphisms and risk of psoriatic arthritis. (2006) (41)
Haemostatic abnormalities in systemic lupus erythematosus. (1983) (41)
Summarizing disease features over time: II. Variability measures of SLEDAI-2K. (2007) (41)
Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Enhances the Ability of SLE Responder Index to Identify Responders in Clinical Trials (2011) (41)
Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. (2015) (40)
Rheumatologic manifestations of infection with the human immunodeficiency virus (HIV). (1990) (40)
Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. (1998) (40)
Differential human leucocyte allele association between psoriasis and psoriatic arthritis: a family-based association study (2012) (40)
Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study (2018) (40)
The Association Between Obesity and Clinical Features of Psoriatic Arthritis: A Case-control Study (2017) (40)
Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months. (2012) (40)
Severe reflex neurovascular dystrophy in childhood. (1985) (40)
Gene expression differences between psoriasis patients with and without inflammatory arthritis. (2015) (40)
Behçet's disease in a patient with immunodeficiency virus infection. (1991) (40)
Effectiveness of psoriatic arthritis therapies. (2003) (40)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2008 (2010) (39)
Validation of the revised and expanded version of the Arthritis Impact Measurement Scales for patients with psoriatic Arthritis. (1996) (39)
The Long-Term Use of Azathioprine in Patients with Psoriatic Arthritis (2001) (39)
Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies (2016) (39)
Effect of Pregnancy on Ankylosing Spondylitis: A Case-Control Study (2011) (39)
Serum Albumin as a Marker for Disease Activity in Patients with Systemic Lupus Erythematosus (2010) (39)
Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group (2017) (39)
The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study (2017) (39)
Nail lesions in systemic lupus erythematosus. (1978) (38)
2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part I: Principles of the Management of Spondyloarthritis in Canada (2015) (38)
Psoriatic Arthritis: Phenotypic Variance and Nosology (2013) (38)
Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set (2016) (38)
Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2019) (38)
Evolving spectrum of mortality and morbidity in SLE (1999) (38)
From Childhood to Adulthood: The Trajectory of Damage in Patients With Juvenile‐Onset Systemic Lupus Erythematosus (2017) (38)
Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis. (2007) (38)
Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes (2011) (38)
PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials (2018) (38)
Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity. (1994) (37)
International spondyloarthritis inter-observer reliability exercise - The inspire study (2006) (37)
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study (2014) (37)
Disease course patterns in systemic lupus erythematosus (2018) (37)
Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study (2016) (37)
Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study (2019) (37)
Increased Expression of B Cell Activation Factor Supports the Abnormal Expansion of Transitional B Cells in Systemic Lupus Erythematosus (2011) (37)
The significance of anticardiolipin antibodies in patients with lupus nephritis (1996) (37)
Updated Guidelines for the Management of Axial Disease in Psoriatic Arthritis (2014) (37)
Coexistence of Fabry's disease and systemic lupus erythematosus. (1998) (37)
Significance of isolated hematuria and isolated pyuria in systemic lupus erythematosus (2001) (37)
Early psoriatic arthritis. (2012) (36)
Enhanced Patient Involvement and the Need to Revise the Core Set — Report from the Psoriatic Arthritis Working Group at OMERACT 2014 (2015) (36)
Development of a Disease Severity and Responder Index for Psoriatic Arthritis (PsA) — Report of the OMERACT 10 PsA Special Interest Group (2011) (36)
Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort (2018) (36)
Mortality studies in SLE: how far can we improve survival of patients with SLE. (2004) (36)
Role of radiation therapy in patients with a diagnosis of both systemic lupus erythematosus and cancer. (2005) (36)
Development of a Disease Activity and Responder Index for Psoriatic Arthritis — Report of the Psoriatic Arthritis Module at OMERACT 11 (2014) (36)
Development of Screening Tools to Identify Psoriatic Arthritis (2010) (36)
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis (2018) (36)
Effect of Psoriatic Arthritis According to the Affected Categories of the International Classification of Functioning, Disability and Health (2010) (36)
HLA studies in psoriatic arthritis: current situation and future needs. (2003) (36)
Differential major histocompatibility complex class I chain-related A allele associations with skin and joint manifestations of psoriatic disease. (2011) (35)
Psoriatic arthritis disease activity during pregnancy and the first-year postpartum. (2017) (35)
Epidemiology of atherosclerosis in systemic lupus erythematosus (2009) (35)
Effectiveness and Safety of Etanercept in Patients with Psoriatic Arthritis in a Canadian Clinical Practice Setting: The REPArE Trial (2011) (35)
Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? a critical appraisal. (2014) (34)
HLA-D region antigens in patients with rheumatoid arthritis. (1991) (34)
Interferon-α induces altered transitional B cell signaling and function in Systemic Lupus Erythematosus. (2015) (34)
Neurocognitive abnormalities in offspring of mothers with systemic lupus erythematosus (2008) (34)
Sickle cell crisis following intraarticular steroid therapy for rheumatoid arthritis. (1987) (34)
Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies (2018) (34)
Longitudinal Analysis of Fatigue in Psoriatic Arthritis (2010) (33)
Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis (2019) (33)
Prognosis and treatment of systemic lupus erythematosus. (1996) (33)
Prevalence and risk factors of low bone mineral density in psoriatic arthritis: A systematic review. (2016) (33)
Association of Variants at 1 q 32 and STAT 3 with Ankylosing Spondylitis Suggests Genetic Overlap with Crohn ’ s Disease (2010) (33)
Methotrexate in systemic lupus erythematosus. (1994) (33)
Pilot study of etretinate in psoriatic arthritis. (1989) (33)
Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics (2020) (33)
Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study (2005) (33)
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2020) (33)
Informing Response Criteria for Psoriatic Arthritis (PsA). II: Further Considerations and a Proposal — The PsA Joint Activity Index (2010) (33)
Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab (2019) (32)
A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach (2016) (32)
Fine mapping of eight psoriasis susceptibility loci (2014) (32)
Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus (2018) (32)
Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities (2020) (32)
Diffuse Idiopathic Skeletal Hyperostosis in Psoriatic Arthritis (2013) (32)
Immunogenetic profile of patients with psoriatic arthritis varies according to the age at onset of psoriasis. (1999) (32)
The impact of the 1997 update of the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus: what has been changed? (2003) (32)
The functional MICA-129 polymorphism is associated with skin but not joint manifestations of psoriatic disease independently of HLA-B and HLA-C. (2013) (32)
Recent advances in understanding and managing psoriatic arthritis (2016) (32)
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study (2020) (31)
Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy. (1999) (31)
Prevalence and predictors of reduced work productivity in patients with psoriatic arthritis. (2014) (31)
Sleep Disturbance in Psoriatic Disease: Prevalence and Associated Factors (2017) (31)
Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. (1994) (31)
Composite Measures in Psoriatic Arthritis: GRAPPA 2008 (2010) (31)
What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis? (2015) (31)
Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus (1993) (31)
Altered Expression of TNF-α Signaling Pathway Proteins in Systemic Lupus Erythematosus (2010) (31)
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF 3 IP 2 (2010) (31)
Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. (2019) (31)
Clinical and Serologic Factors Associated with Lupus Pleuritis (2010) (31)
Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling (2017) (31)
Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease (2012) (31)
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long‐Term Extension Studies (2019) (31)
Non-Lymphoma Hematological Malignancies in Systemic Lupus Erythematosus (2013) (30)
Informing Response Criteria for Psoriatic Arthritis. I: Discrimination Models Based on Data from 3 Anti-Tumor Necrosis Factor Randomized Studies (2010) (30)
The use of ultrasound for the assessment of enthesitis in patients with spondyloarthritis. (2013) (30)
Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. (2006) (30)
Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report (2019) (30)
Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study (2004) (30)
Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website (2013) (30)
Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. (2010) (30)
Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus (2019) (30)
Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus (2011) (30)
Prevalence and Risk Factors for Liver Biochemical Abnormalities in Canadian Patients with Systemic Lupus Erythematosus (2012) (29)
The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA–B27 Status? (2020) (29)
Recognizing psoriatic arthritis in the dermatology clinic. (2010) (29)
Patient-reported Outcome in Psoriatic Arthritis: A Comparison of Web-based Versus Paper-completed Questionnaires (2011) (29)
Hospitalizations in Patients with Systemic Lupus Erythematosus in an Academic Health Science Center (2017) (29)
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study (2018) (29)
Disease expression and class II HLA antigens in systemic lupus erythematosus (1999) (29)
Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered? (2018) (29)
Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP 1 (2015) (29)
OMERACT 7 psoriatic arthritis workshop: synopsis (2005) (29)
Development of Criteria to Distinguish Inflammatory from Noninflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2013 Annual Meeting (2014) (29)
Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis (2008) (29)
Prognosis of systemic lupus erythematosus and factors that affect it (1991) (29)
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies (2021) (29)
Cardiovascular Comorbidities in Psoriasis and Psoriatic Arthritis: Pathogenesis, Consequences for Patient Management, and Future Research Agenda: A Report from the GRAPPA 2009 Annual Meeting (2011) (29)
Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis (2016) (29)
Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus (2018) (29)
Criteria for assessing disease activity in systemic lupus erythematosus. (1989) (29)
Lost-to-follow-up study in systemic lupus erythematosus (SLE) (2000) (29)
Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50: A Reliable Index for Measuring Improvement in Disease Activity (2011) (29)
American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort (2014) (28)
Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis (2019) (28)
Prolonged complete remission in previously severe SLE. (1982) (28)
Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis (2018) (28)
Psoriatic arthritis precipitated by physical trauma. (1990) (28)
Monoclonal gammopathy in systemic lupus erythematosus (2007) (28)
Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus (2015) (27)
Breast Cancer in Systemic Lupus Erythematosus (2013) (27)
PPAR-gamma gene polymorphisms and psoriatic arthritis. (2006) (27)
Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus (2019) (27)
The utility of the arthritis impact measurement scales for patients with psoriatic arthritis. (1992) (27)
Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? (1995) (27)
Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach (2020) (27)
The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts (2016) (27)
Reliability of Radiographic Scoring Methods in Axial Psoriatic Arthritis (2014) (27)
Towards international guidelines for the management of psoriatic arthritis. (2006) (27)
Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study (2006) (27)
Primary malignant lymphoma of the spleen in systemic lupus erythematosus. (1989) (26)
Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies (2020) (26)
Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease (2009) (26)
Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study (2010) (26)
Bowel involvement in systemic lupus erythematosus: Crohn's disease or lupus vasculitis? (1985) (26)
Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting (2016) (26)
Chronic adhesive lupus serositis as a complication of systemic lupus erythematosus. Refractory chest pain and small-bowel obstruction. (1984) (26)
Toronto Psoriatic Arthritis Screening (ToPAS) Questionnaire: A Report from the GRAPPA 2009 Annual Meeting (2011) (26)
Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus (2019) (26)
Disease evolution in late-onset and early-onset systemic lupus erythematosus (2017) (26)
Variability and correlates of high sensitivity C-reactive protein in systemic lupus erythematosus (2009) (26)
Alterations in circulating fatty acid composition in patients with systemic lupus erythematosus: a pilot study. (2011) (26)
Pericardial fluid analysis in scleroderma (systemic sclerosis). (1976) (25)
Atherosclerosis and systemic lupus erythematosus (2000) (25)
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies (2018) (25)
The correlation between carotid artery atherosclerosis and clinical ischemic heart disease in lupus patients (2014) (25)
Association of SEEK1 and psoriatic arthritis in two distinct Canadian populations (2005) (25)
Comparison of three anti-dsDNA assays: performance and correlation with systemic lupus erythematosus disease activity. (2013) (25)
European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance (2021) (25)
Psoriatic arthritis (2009) (25)
Brain scan diagnosis of central nervous system involvement in systemic lupus erythematosus. (1978) (24)
A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index (2018) (24)
Repair of Radiographic Joint Damage Following Treatment with Etanercept in Psoriatic Arthritis Is Demonstrable by 3 Radiographic Methods (2011) (24)
Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients (2017) (24)
Systemic lupus erythematosus: an update on current pharmacotherapy and future directions (2013) (24)
SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years (2012) (24)
Biologic therapy of psoriatic arthritis. (2011) (24)
Predictive Utility of Cardiovascular Risk Prediction Algorithms in Inflammatory Rheumatic Diseases: A Systematic Review (2019) (24)
Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers (2009) (23)
Toward unraveling the mystery of psoriatic arthritis. (1993) (23)
HLA-DRB1*04 alleles in psoriatic arthritis: comparison with rheumatoid arthritis and healthy controls. (2001) (23)
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials (2020) (23)
Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial (2017) (23)
Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. (2012) (23)
Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus (2020) (23)
Glucocorticoid receptors in systemic lupus erythematosus. (1991) (23)
Musculoskeletal surgery in psoriatic arthritis. (1998) (23)
Aortitis and spondyloarthritis--an unusual presentation: case report and review of the literature. (2010) (23)
Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia (2017) (23)
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1) (2018) (23)
Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis (2020) (22)
Successful pregnancy in systemic lupus erythematosus with an untreated lupus anticoagulant. (1988) (22)
Measuring participation in people with spondyloarthritis using the social role participation questionnaire (2011) (22)
Association of nuclear factor-kappaB in psoriatic arthritis. (2005) (22)
Shrinking lung syndrome in systemic lupus erythematosus: a single-centre experience (2018) (22)
Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research (2020) (22)
Breast cancer in systemic lupus (2017) (22)
Axial involvement in psoriatic arthritis: An update for rheumatologists. (2021) (22)
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. (2020) (22)
Significance of Clinical Evaluation of the Metacarpophalangeal Joint in Relation to Synovial/Bone Pathology in Rheumatoid and Psoriatic Arthritis Detected by Magnetic Resonance Imaging (2009) (22)
Classification and Outcome Measures for Psoriatic Arthritis (2018) (22)
Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients With Psoriatic Disease (2019) (22)
Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. (2008) (22)
Biomarkers in Psoriasis and Psoriatic Arthritis: GRAPPA 2008 (2010) (22)
Longitudinal cohort studies. (2005) (21)
Comparison of clinical and immunogenetic features in familial versus sporadic psoriatic arthritis. (2000) (21)
Discussion: Clinical features, epidemiology, classification criteria, and quality of life in psoriasis and psoriatic arthritis (2005) (21)
A variant of the IL4 I50V single-nucleotide polymorphism is associated with erosive joint disease in psoriatic arthritis. (2008) (21)
OP0229 THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021 (2021) (21)
Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index (2020) (21)
Cytotoxic therapy in systemic lupus erythematosus. Experience from a single center. (1997) (21)
Selective deficiency of the fourth component of complement in a patient with systemic lupus erythematosus (SLE): immunochemical and biological studies. (1981) (20)
Recommendations for Frequency of Visits to Monitor Systemic Lupus Erythematosus in Asymptomatic Patients: Data from an Observational Cohort Study (2013) (20)
Psoriasis in systemic lupus erythematosus: a single-center experience (2017) (20)
Skin nontuberculous mycobacterial infection in systemic lupus erythematosus: an unusual skin infection mimicking lupus vasculitis. (2013) (20)
The effectiveness of leflunomide in psoriatic arthritis. (2014) (20)
Imaging in Psoriasis and Psoriatic Arthritis: GRAPPA 2008 (2010) (20)
Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. (1994) (20)
Benchmarking Care in Psoriatic Arthritis — The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting (2017) (20)
Relationship of the Arthritis Impact Measurement Scales to changes in articular status and functional performance in patients with psoriatic arthritis. (1996) (20)
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort (2021) (20)
The Systemic Lupus International Collaborating Clinics Group - origins and outcomes (2001) (20)
Cultural syndromes and age moderate the emotional impact of illness intrusiveness in rheumatoid arthritis. (2009) (19)
The International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: A Report from the GRAPPA 2013 Meeting (2014) (19)
Impaired antigen-specific suppressor cell activity in psoriasis and psoriatic arthritis. (1981) (19)
Performance of scored palpation, a point count, and dolorimetry in assessing unsuspected nonarticular tenderness. (1993) (19)
Antimalarials as a risk factor for elevated muscle enzymes in systemic lupus erythematosus (2016) (19)
Cortisol catabolism by lymphocytes of patients with systemic lupus erythematosus and rheumatoid arthritis. (1990) (19)
The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus (2021) (19)
Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA) (2018) (19)
Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis (2019) (19)
Rheumatoid pleural effusion: lack of response to intrapleural corticosteroid. (1986) (19)
Functional impairment measurement in psoriatic arthritis: Importance and challenges. (2018) (19)
High resolution mapping in the major histocompatibility complex region identifies multiple independent novel loci for psoriatic arthritis (2011) (19)
Nasal-septal perforation in systemic lupus erythematosus--time for a closer look. (1999) (19)
Neuropsychiatric lupus. (1980) (19)
Type and outcome of reconstructive surgery for different patterns of psoriatic arthritis. (2000) (18)
Damage in lupus patients—what have we learned so far? (2013) (18)
The Spondyloarthritis Research Consortium of Canada Registry for Spondyloarthritis (2011) (18)
Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice (2017) (18)
SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study (2018) (18)
Optimal Frequency of Visits for Patients with Systemic Lupus Erythematosus to Measure Disease Activity Over Time (2011) (18)
Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide. (2007) (18)
Consensus exercise on domains in psoriatic arthritis (2005) (18)
Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus. (1993) (18)
Systemic lupus erythematosus in a patient with C4 deficiency. (1981) (18)
Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach (2018) (18)
Physician scores vs patient self-report of joint and skin manifestations in psoriatic arthritis. (2013) (18)
Item weightings for the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Disease Damage Index using Rasch analysis do not lead to an important improvement. (2003) (18)
Spinal mobility measures in spondyloarthritis: application of the OMERACT filter. (2007) (18)
Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls (2018) (18)
Hydroxychloroquine-Induced Cardiomyopathy in Systemic Lupus Erythematosus. (2016) (18)
210. Effect of Certolizumab Pegol Over 48 Weeks on Signs and Symptoms in Patients with Psoriatic Arthritis with and Without Prior Tumor Necrosis Factor Inhibitor Exposure (2014) (18)
Measurement properties of the minimal disease activity criteria for psoriatic arthritis (2019) (17)
Mortality in psoriatic arthritis: Risk, causes of death, predictors for death. (2020) (17)
SAT0408 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled Trials (2014) (17)
Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus (2015) (17)
Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment (2018) (17)
Quantifying Differences in Heritability among Psoriatic Arthritis (PsA), Cutaneous Psoriasis (PsC) and Psoriasis vulgaris (PsV) (2019) (17)
Prognosis of systemic lupus erythematosus and the factors that affect it. (1990) (17)
217. Long-Term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1) (2015) (17)
The Systemic Lupus International Collaborating Clinics (SLICC) group – It was 20 years ago today (2011) (17)
Aspects of use of antimalarials in systemic lupus erythematosus. (1998) (17)
Tracing studies and analysis of the effect of loss to follow‐up on mortality estimation from patient registry data (2003) (17)
Isolated Hematuria and Sterile Pyuria May Indicate Systemic Lupus Erythematosus Activity (2015) (17)
Psoriatic arthritis clinical registries and genomics (2005) (17)
Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis (2018) (17)
23 – EPIDEMIOLOGY OF SYSTEMIC LUPUS ERYTHEMATOSUS (2004) (17)
Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus (2015) (16)
Atherosclerotic Vascular Events in Systemic Lupus Erythematosus: An Evolving Story (2019) (16)
Severe brady-arrhythmias in systemic lupus erythematosus: prevalence, etiology and associated factors (2018) (16)
Role of specialty care in the management of patients with systemic lupus erythematosus. (2002) (16)
Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: Results from ADEPT (2005) (16)
Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective (2018) (16)
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis (2019) (16)
Impaired antigen-specific suppressor cell activity in patients with systemic lupus erythematosus. (1980) (16)
Atypical erosive osteoarthritis and Sjögren's syndrome. (1986) (16)
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study (2020) (16)
Association of variably expressed KIR3dl1 alleles with psoriatic disease (2017) (16)
HLA and disease manifestations in rheumatoid arthritis--a Canadian experience. (1986) (16)
Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results From the GO-REVEAL Study. (2009) (16)
How can we define low disease activity in systemic lupus erythematosus? (2019) (16)
Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2012 Annual Meeting (2013) (15)
The Use of Micronutrient Supplements Is Not Associated with Better Quality of Life and Disease Activity in Canadian Patients with Systemic Lupus Erythematosus (2010) (15)
Prevalence of Monoclonal Gammopathy Among Patients with Psoriatic Arthritis (2012) (15)
Thrombovascular Events Affect Quality of Life in Patients with Systemic Lupus Erythematosus (2011) (15)
Sensitivity and Specificity of Radiographic Scoring Instruments for Detecting Change in Axial Psoriatic Arthritis (2017) (15)
Atherosclerosis and Lupus — The SLICC study (2007) (15)
OP0169 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials (2015) (15)
Arthritis Mutilans: A Report from the GRAPPA 2012 Annual Meeting (2013) (15)
Switching Treatment Between Mycophenolate Mofetil and Azathioprine in Lupus Patients: Indications and Outcomes (2014) (15)
GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies (2017) (15)
Clinical and genetic registries in psoriatic disease. (2008) (15)
Further Evidence Supporting a Parent‐of‐Origin Effect in Psoriatic Disease (2015) (15)
The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis. (2019) (15)
Burden of autoantibodies and association with disease activity and damage in systemic lupus erythematosus. (2010) (15)
Relationship between cardiac symptoms, myocardial perfusion defects and coronary angiography findings in systemic lupus erythematosus (2011) (15)
Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis. (2018) (14)
Identifying and Characterizing Psoriasis and Psoriatic Arthritis Patients in Ontario Administrative Data: A Population-based Study From 1991 to 2015 (2020) (14)
The SLICC inception cohort for atherosclerosis (2008) (14)
New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE (2021) (14)
Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis (2016) (14)
Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2011) (14)
From Childhood to Adulthood: Disease Activity Trajectories in Childhood‐Onset Systemic Lupus Erythematosus (2018) (14)
Review of Clinical Registries of Psoriatic Arthritis: Lessons Learned? Value for the Future? (2011) (14)
Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort (2018) (14)
Late mortality in SLE--"the price we pay for control". (1980) (14)
Predictors for clinical outcome in psoriatic arthritis – what have we learned from cohort studies? (2014) (14)
Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials? (2018) (14)
Does Renin‐Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case–Control Study (2016) (14)
Addressing comorbidities in psoriatic disease (2018) (13)
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach (2020) (13)
Association of killer cell immunoglobulin–like receptor genotypes with vascular arterial events and anticardiolipin antibodies in patients with lupus (2008) (13)
The Association Between HLA Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis (2018) (13)
FRI0509 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 24 months in patients with active psoriatic arthritis: interim data from opal balance, an open-label, long-term extension study (2017) (13)
Psoriatic Arthritis in Canadian Clinical Practice: The PsA Assessment in Rheumatology (2012) (13)
Methods for analyzing observational longitudinal prognosis studies for rheumatic diseases: a review & worked example using a clinic-based cohort of juvenile dermatomyositis patients (2017) (13)
Psoriatic arthritis: recognition and management. (1998) (13)
The clinical assessment of patients with psoriatic arthritis (PsA): Results of a validation study of the Spondyloarthritis Research Consortium of Canada (2003) (13)
Treating Psoriatic Arthritis to Target: Defining the Psoriatic Arthritis Disease Activity Score That Reflects a State of Minimal Disease Activity (2020) (13)
Trends in Mortality and Cause-specific Mortality among patients with Psoriasis and Psoriatic Arthritis in Ontario, Canada. (2020) (13)
Patient Participation in Psoriasis and Psoriatic Arthritis Outcome Research: A Report from the GRAPPA 2013 Annual Meeting (2014) (13)
Psoriatic arthritis. (2000) (13)
Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort (2019) (13)
Imputation-based analysis of MICA alleles in the susceptibility to ankylosing spondylitis (2018) (13)
More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus (2018) (12)
Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort (2020) (12)
Glomerular filtration rate predicts arterial events in women with systemic lupus erythematosus. (2011) (12)
Magnetic Resonance Imaging in Psoriatic Arthritis: A Descriptive Study of Indications, Features and Effect on Treatment Change (2017) (12)
International symposium on psoriatic arthritis. (1992) (12)
UGT2B17 copy number gain in a large ankylosing spondylitis multiplex family (2013) (12)
Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies (2021) (12)
Liver Abnormalities in Patients with Psoriatic Arthritis (2019) (12)
Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2021) (12)
Current and investigational treatment of psoriatic arthritis (2004) (12)
Gender-related differences in patients with psoriatic arthritis (2012) (12)
Development and Assessment of Users’ Satisfaction with the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website (2013) (12)
Prologue: 2010 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2012) (12)
Inflammatory Spinal Disease in Psoriatic Arthritis: A Report from the GRAPPA 2010 Annual Meeting (2012) (12)
High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. (2012) (12)
Introduction/overview on clinical registries (2005) (12)
Premature coronary artery disease in systemic lupus erythematosus in the absence of corticosteroid use. (2000) (12)
Axial Disease in Psoriatic arthritis: The presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort. (2021) (12)
Long‐term outcome of early neuropsychiatric events due to active disease in systemic lupus erythematosus (2012) (12)
OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials (2014) (12)
Disease Outcomes in Glucocorticosteroid‐Naive Patients With Systemic Lupus Erythematosus (2017) (11)
Traditional and Newer Therapeutic Options for Psoriatic Arthritis (2012) (11)
Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada (2018) (11)
Pulmonary hypertension in systemic lupus erythematosus. (1985) (11)
Prologue: 2011 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2012) (11)
Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2013) (11)
Followup in psoriatic arthritis: relationship to disease characteristics. (1992) (11)
What Is Axial Psoriatic Arthritis? (2018) (11)
Outcomes of the 2019 GRAPPA Workshop on Continuous Composite Indices for the Assessment of Psoriatic Arthritis and Membership-recommended Next Steps (2020) (11)
Medication Use in Systemic Lupus Erythematosus (2011) (11)
Aberrations in T-cell subpopulations in patients with psoriasis and psoriatic arthritis. (1983) (11)
The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set (2019) (11)
Atherosclerosis in Systemic Lupus Erythematosus - Epidemiology, Risk Factors, Subclinical Assessment and Future Study (2013) (11)
Stress fractures of the legs and swelling of the ankles in a patient with lupus: a diagnostic dilemma. (1990) (11)
Systematic Review of the Quality of Prognosis Studies in Systemic Lupus Erythematosus (2014) (10)
Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign (2013) (10)
Can we identify psoriatic arthritis early? (2008) (10)
The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis. (2019) (10)
Chapter 46 – Clinical Measures, Metrics, and Indices (2013) (10)
GRAPPA Responder Index Project (GRACE): A Report from the GRAPPA 2011 Annual Meeting (2012) (10)
FRI0498 Outcomes associated with achievement of various treatment targets in patients with psoriatic arthritis receiving adalimumab (2017) (10)
Malignancy in psoriatic disease: Results from prospective longitudinal cohorts. (2020) (10)
Current Controversies in Spondyloarthritis: SPARTAN (2010) (10)
Outcome measures in systemic lupus erythematosus (2013) (10)
Discordance between HLA-B27 and ankylosing spondylitis: a family investigation. (1986) (10)
Prognostic implications of active discoid lupus erythematosus and malar rash at the time of diagnosis of systemic lupus erythematosus: Results from a prospective cohort study (2016) (10)
Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease (2017) (10)
Patterns of peripheral joint involvement in psoriatic arthritis-Symmetric, ray and/or row? (2018) (10)
Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients (2019) (10)
HLA antigens and nailfold capillary microscopy studies in patients with insulin dependent and noninsulin dependent diabetes mellitus and limited joint mobility. (1990) (10)
Dermatology Screening Tools: Project Update from the GRAPPA 2012 Annual Meeting (2013) (10)
Lack of association of SLC22A4, SLC22A5, SLC9A3R1 and RUNX1 variants in psoriatic arthritis. (2005) (10)
Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus (2021) (10)
Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort (2020) (10)
OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES (2020) (10)
Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. (2021) (10)
A hot spot for systemic lupus erythematosus, but not for psoriatic arthritis, identified by spatial analysis suggests an interaction between ethnicity and place of residence. (2013) (10)
Editorial: What Is Peripheral Spondyloarthritis? (2015) (10)
Development of a Modified Psoriatic Arthritis Disease Activity Score Using the Medical Outcomes Study Short Form 12 as a Measure of Quality of Life (2020) (10)
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study (2021) (10)
Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials (2020) (10)
Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting (2018) (10)
Building Bridges between Researchers and Patient Research Partners: A Report from the GRAPPA 2014 Annual Meeting (2015) (10)
Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting (2018) (9)
AB0160 Epigenetic Studies in Maternally versus Paternally Transmitted Psoriatic Disease (2014) (9)
A Comparison of 2019 EULAR/ACR SLE Classification Criteria with Two Sets of Earlier SLE Classification Criteria. (2020) (9)
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance (2019) (9)
Prologue: 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2014) (9)
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis (2020) (9)
Does the change in season affect disease activity in patients with psoriatic arthritis? (2012) (9)
The Association of HLA-class I Genes and the Extent of Atherosclerotic Plaques in Patients with Psoriatic Disease (2016) (9)
Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics (2017) (9)
Should all patients with systemic lupus erythematosus receive cardioprotection with statins? (2007) (9)
Absence of an association between HLA typing in cystic fibrosis arthritis and hypertrophic osteoarthropathy. (1991) (9)
Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria (2021) (9)
Declining levels of serum chemokine (C‐X‐C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker? * (2020) (9)
Spondyloarthropathies: Targeted therapy for psoriatic arthritis (2009) (8)
Atlantoaxial subluxation in a patient with psoriatic arthritis. (1989) (8)
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1 (2021) (8)
Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus (2021) (8)
Prologue: 2016 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2017) (8)
Physician’s Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study (2018) (8)
Incidence of and Risk Factors for Heart Failure in Patients With Psoriatic Disease: A Cohort Study (2021) (8)
Standardizing the monitoring of outcome measures: imaging in psoriatic arthritis (2011) (8)
The Relationship Between Physical Examination and Ultrasonography of Large Entheses of the Achilles Tendon and Patellar Tendon Origin (2019) (8)
Cancer risk in a large inception SLE cohort: Effects of demographics, smoking, and medications. (2020) (8)
Should methotrexate remain the first-line drug for psoriasis? (2017) (8)
Psoriasis treatment: current and emerging directed therapies. Discussion (2005) (8)
Established criteria for disease controlling drugs in ankylosing spondylitis (2003) (8)
Monophasic Disease Course in Systemic Lupus Erythematosus (2018) (8)
Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus (2020) (8)
Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set (2018) (8)
Depression and Anxiety Reduce the Probability of Achieving a State of Sustained Minimal Disease Activity in Patients With Psoriatic Arthritis (2021) (7)
Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort (2022) (7)
Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting (2019) (7)
Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Psoriatic Arthritis. (2014) (7)
Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial (2020) (7)
Health Care Utilization for Musculoskeletal Issues During the Prediagnosis Period in Psoriatic Arthritis: A Population‐Based Study (2020) (7)
Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis. (2019) (7)
SAT0270 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis (2018) (7)
Radiographic reports in osteonecrosis of the hip in systemic lupus erythematosus. (1998) (7)
Barriers to medication adherence and degree of nonadherence in a systemic lupus erythematosus (SLE) outpatient population (2021) (7)
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort (2022) (7)
Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis (2021) (7)
The Path Forward to Biomarker Discovery in Psoriatic Disease: A Report from the GRAPPA 2010 Annual Meeting (2012) (7)
The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 Updates (2020) (7)
GRAPPA 2019 Project Report (2020) (7)
Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHC (2019) (7)
Prologue: 2014 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2015) (7)
Let’s Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting (2016) (7)
Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting (2021) (7)
Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index (2020) (7)
GRAPPA 2018 Project Report (2019) (7)
The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort. (2017) (7)
Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. (2019) (7)
Malar rash in a patient with Reiter's syndrome--a clue for the diagnosis of human immunodeficiency virus infection. (1990) (7)
Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study (2022) (7)
Genomewide association study in Ankylosing spondylitis identifies major Non-MHC genetic determinants of disease susceptibility (2008) (7)
Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study (2016) (7)
QUALITY OF LIFE IN SLE DURING ACTIVE AND INACTIVE DISEASE STATES: DIFFERENTIAL CONTRIBUTORS TO MENTAL AND PHYSICAL HEALTH (1999) (7)
Summary of the 2005 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). (2006) (6)
SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement (2015) (6)
Accuracy of self-reported family history in psoriatic arthritis. (2000) (6)
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial (2022) (6)
OP0077 Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Psoriatic Arthritis with and without Prior Anti-Tumor Necrosis Factor Exposure: 96-Week Outcomes from the Rapid-Psa Trial (2014) (6)
Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable? (2020) (6)
Prevalence and Factors Associated With Osteoporosis and Bone Mineral Density Testing in Psoriatic Arthritis (2020) (6)
Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index (2020) (6)
Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting (2015) (6)
EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19 SUBUNIT OF IL-23, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-52 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES (2021) (6)
Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis (2020) (6)
Evolving concepts in systemic lupus erythematosus damage assessment (2021) (6)
Early-onset obesity and risk for psoriatic arthritis. (2010) (6)
The Need to Define Musculoskeletal Inflammation: A Report from the GRAPPA 2010 Annual Meeting (2012) (6)
Faculty Opinions recommendation of A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. (2019) (6)
Acquired low immunoglobulin levels and risk of clinically relevant infection in adult patients with systemic lupus erythematosus: a cohort study. (2020) (6)
Propensity Score Methods in Rare Disease: A Demonstration Using Observational Data in Systemic Lupus Erythematosus (2020) (6)
Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties (2019) (6)
The relationship between patient satisfaction with health and clinical measures of function and disease status in patients with psoriatic arthritis. (2000) (6)
AB0758 Change in Weight from Baseline during the Palace Clinical Trial Program with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials (2014) (6)
Role of radiation therapy in patients with both a diagnosis of lupus and cancer (2003) (6)
Radiological characteristics of the calcaneal spurs in psoriatic arthritis. (2014) (6)
Psoriatic Arthritis and Psoriasis (2016) (6)
Association of Nuclear Factor- κ B in Psoriatic Arthritis (2005) (6)
The apolipoprotein E2 isoform is associated with accelerated onset of coronary artery disease in systemic lupus erythematosus. (2008) (6)
SAT0271 Secukinumab, a fully human anti-interleukin-17a monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52-week treatment period (2018) (5)
Prologue: 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2016) (5)
Abatacept in the Treatment of Active Psoriatic Arthritis : 24-Week Results from a Phase III Study (2017) (5)
A novel, disease-specific quality-of-life instrument for patients with SLE (2006) (5)
Successful treatment of steroid-resistant Weber – Christian disease with biliary ductopenia using cyclosporin (5)
Axial Psoriatic Arthritis (2021) (5)
Immunoglobulin levels in systemic lupus erythematosus: A narrative review (2021) (5)
Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations (2020) (5)
Epidemiology of systemic lupus erythematosus (2004) (5)
Faculty Opinions recommendation of Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. (2019) (5)
Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort (2021) (5)
GRAPPA 2007: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. (2008) (5)
Remission in psoriatic arthritis: Definition and predictors. (2020) (5)
THU0431 The Prediction and Benefits of Minimal Disease Activity in Patients with Psoriatic Arthritis in the Adept Trial (2015) (5)
Psoriatic Arthritis (1998) (5)
SAT0273 The Characteristics and Predictors of Minimal Disease Activity in Patients with Psoriatic Arthritis on TNF Blockers (2013) (5)
The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. (2021) (5)
Assessment of Coronary Risk Based on Cumulative Exposure to Lipids in Systemic Lupus Erythematosus (2013) (5)
Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib (2021) (5)
Discussion: Assessment of psoriatic arthritis (2005) (5)
Oxford Textbook of Psoriatic Arthritis (2018) (5)
OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial (2017) (5)
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE) (2022) (5)
397 Fifty two-week efficacy and safety results from SPIRIT-P1: A Phase 3 study of ixekizumab in patients with active psoriatic arthritis (2017) (5)
Corneodesmosin polymorphisms in psoriatic arthritis. (2005) (4)
Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data (2021) (4)
Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies (2021) (4)
Proceedings of the GRAPPA 2016 Retreat (2017) (4)
Future Trends in Research in Psoriatic Arthritis (2012) (4)
THU0432 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials (2016) (4)
The Systemic Lupus International Collaborating Clinics (SLICC) Group – It Was 20 Years Ago Today (2012) (4)
Medium Versus High Initial Prednisone Dose for Remission Induction in Lupus Nephritis: A Propensity Score–Matched Analysis (2021) (4)
Antimalarial-Induced Cardiomyopathy Resembles Fabry Disease on Cardiac MRI. (2019) (4)
Reporting of mortality in a psoriatic arthritis clinic is primarily a function of the number of clinic contacts and not disease severity. (2005) (4)
Assessment of disease activity in lupus (1992) (4)
Vascular- and pregnancy-related outcomes in patients with systemic lupus erythematosus with positive antiphospholipid profile and thrombocytopenia (2015) (4)
On Modelling Minimal Disease Activity (2016) (4)
AB0746 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, and the Impact of Baseline Weight and BMI on ACR20 and HAQ-DI Response: Pooled Results from 3 Phase 3, Randomized, Controlled Trials (2014) (4)
Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study (2022) (4)
Psoriatic arthritis. (1998) (4)
DEVELOPING AN IPAD® APPLICATION FOR DATA COLLECTION IN A RHEUMATOLOGY RESEARCH CLINIC (2015) (4)
Assessing Prognosis in Rheumatoid Arthritis Using Monoclonal Antibodies and Flow Cytometry (1997) (4)
GRAPPA 2015 Research and Education Project Reports (2016) (4)
Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. (2020) (4)
Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis (2020) (4)
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo (2020) (4)
Prologue: 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2018) (4)
OP0109 Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from A Phase 3 Study (Spirit-P1) (2016) (4)
Response criteria for cutaneous SLE in clinical trials. (2007) (4)
THU0420 Long-Term (104-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomised, Controlled Trial and Open-Label Extension (Palace 1) (2015) (4)
Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial (2022) (4)
Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis (2020) (4)
The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database (2018) (4)
Factors Associated With Rapid Progression to Endstage Kidney Disease in Lupus Nephritis (2020) (4)
Evaluating the Construct of Damage in Systemic Lupus Erythematosus (2021) (4)
Inspire lateral flexion: A new method to measure lateral spinal mobility in patients with spondyloarthritis (SpA) (2006) (4)
OP0080 Impact of Persistent Minimal Disease Activity on Long-Term Outcomes in Psoriatic Arthritis: Results from 5 Years of the Long Term Extension of A Randomized, Placebo-Controlled, Study (2014) (4)
Biomarkers for Comorbidities in Psoriasis: A Report from the Grappa 2011 Annual Meeting (2012) (4)
The Genetic Basis of Spondyloarthritis: SPARTAN/IGAS 2009 (2010) (4)
Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT (2005) (4)
Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease (2008) (3)
Genome-wide association analysis of psoriatic arthritis (2014) (3)
SAT0305 MDA criteria for PSA show good correlation with physician and patient opinions and with proposed composite measures (2013) (3)
Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative (2020) (3)
AB0824 WHICH PARAMETERS ARE RELEVANT IN THE IDENTIFYING AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS? – RESULTS OF A SURVEY AMONG ASAS AND GRAPPA MEMBERS (2020) (3)
Isolated axial disease in psoriatic arthritis and ankylosing spondylitis with psoriasis (2022) (3)
Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset (2021) (3)
FRI0339 LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2) (2020) (3)
Best-practice Indicators in Psoriatic Disease Care (2019) (3)
PSORIATIC SPONDYLARTHROPATHY: A LONG TERM PROSPECTIVE STUDY (1988) (3)
Quantifying Differences in Heritability among Psoriatic Arthritis (PsA), Cutaneous Psoriasis (PsC) and Psoriasis vulgaris (PsV) (2019) (3)
Leflunomide in the treatment of psoriatic arthritis and psoriasis: Joint and skin efficacy and safety in the TOPAS study (2003) (3)
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis (2022) (3)
OP0111 The association between sonographic enthesitis and radiographic joint damage in psoriatic arthritis (2017) (3)
Secukinumab provides sustained pasdas related low disease activity in psoriatic arthritis: two year results from the future 2 study (2018) (3)
Relationship between C-reactive protein (CRP) concentration and joint damage in psoriatic arthritis (PSA): Subanalysis of placebo- and adalimumab-treated patients in adept (2007) (3)
Oral Abstracts 1: Connective Tissue DiseaseO1. Long-Term Outcomes of Children Born to Mothers with SLE (2013) (3)
OMERACT Filter 2.1 Instrument Selection for Physical Function Domain in Psoriatic Arthritis: Provisional Endorsement for HAQ-DI and SF-36 PF. (2021) (3)
AB0822 Therapeutic Response in Adalimumab-Treated Patients with Psoriatic Arthritis in Relation to Weight (2015) (3)
University of Toronto Lupus Clinic Turns 40 (2012) (3)
Psoriatic arthritis (2000) (3)
Tofacitinib for Psoriatic Arthritis. (2018) (3)
FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR) (2020) (3)
Comparison Between INSPIRE and Domjan method for measuring lumbar lateral flexion in patients of psoriatic arthritis (PsA) and correlation with radiographic damage (2018) (3)
The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial (2022) (3)
Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2014 Annual Meeting (2015) (3)
Expression patterns of natural killer receptor genes in inflamed joints and peripheral blood of patients with psoriatic arthritis. (2011) (3)
LONG-TERM RADIOGRAPHIC OUTCOME IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB : 104 WEEK RESULTS FROM THE GO-REVEAL STUDY (2012) (3)
Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure. (2014) (3)
On Defining Musculoskeletal Inflammation: A Report from the GRAPPA 2011 Annual Meeting (2012) (3)
A novel role for the psoriatic arhtirtis impact of disease (PsAID) questionnaire. (2019) (3)
Systemic Lupus Erythematosus : A Systematic Review Optimal Monitoring For Coronary Heart Disease Risk in Patients with (2015) (3)
S1D:5 Sle disease activity index glucocorticosteroid index (sledai-2kg) identifies more responders than sledai-2k (2018) (3)
Case Report of Refractory Psoriatic Arthritis Achieving Remission Using Nigella sativa (Black Seed Oil) Extract (2020) (3)
Prognosis of systemic lupus erythematosus and factors that affect it. (1992) (3)
Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications (2021) (3)
Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE (2022) (3)
Rituximab for Sight-Threatening Lupus-Related Retinal Vasculitis. (2017) (3)
Development validation and reliability of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 (2012) (2)
SAT0260 Effect of Certolizumab Pegol on the Multiple Facets of Psoriatic Arthritis as Reported by Patients with and without Prior Anti-Tnf Exposure: 24-Week Patient-Reported Outcome Results of Rapid-PSA Study (2013) (2)
Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Braun and Landewé (2022) (2)
Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting. (2021) (2)
OP0042 Do We Know How and When to Stop Immunosuppressants in Lupus Patients? (2014) (2)
Nonlymphoma hematological malignancies in systemic lupus erythematosus (2012) (2)
Immunoglobulin G Subclass Analysis in Psoriatic Arthritis (2014) (2)
OP0221 TARGETED METABOLOMIC PROFILING AND PREDICTION OF CARDIOVASCULAR EVENTS: A PROSPECTIVE STUDY OF PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS (2)
THU0300 Network meta-analysis of tofacitinib vs bdmards or apremilast for the treatment of tnf inhibitor-naÏve patients with psoriatic arthritis (2018) (2)
Is it time for treat to target in psoriatic arthritis? (2015) (2)
Certolizumab Pegol is Associated with Long-Term Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: 4-Year Outcomes from the Rapid-Psa Study (2016) (2)
Improvements In Productivity At Paid Work And Within Household, And Increased Participation In Daily Activities After 24 Weeks Of Certolizumab Pegol Treatment Of Patients With Psoriatic Arthritis: Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study (2013) (2)
Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. (2020) (2)
Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis (2021) (2)
Chapter 3 – Clinical Features of Psoriatic Arthritis (2007) (2)
FRI0470 Long-Term (156-Week) Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials (2016) (2)
60 Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset with SLE (2019) (2)
Faculty Opinions recommendation of Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: Results through week 24 of the GO-VIBRANT study. (2019) (2)
Prologue: 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2019) (2)
O03 Apremilast, an Oral Phosphodiesterase-4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III Randomized Controlled Trials (2016) (2)
Oligoarticular vs Polyarticular Psoriatic Arthritis: A Longitudinal Study Showing Similar Characteristics (2021) (2)
A26: Longitudinal Disease Trajectory of Juvenile Dermatomyositis (2014) (2)
Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis. (2020) (2)
Faculty Opinions recommendation of A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. (2011) (2)
FRI0471 Certolizumab Pegol for The Treatment of Psoriatic Arthritis: 4-Year Outcomes from The Rapid-Psa Trial (2016) (2)
Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial (2022) (2)
Faculty Opinions recommendation of Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. (2016) (2)
Effect Of Certolizumab Pegol On The Multiple Facets Of Psoriatic Arthritis As Reported By Patients: 24-Week Patient Reported Outcome Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study (2013) (2)
Presidential Round Table: A Report from the GRAPPA Annual Meeting (2016) (2)
Etanercept for psoriatic arthritis (2010) (2)
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group (2021) (2)
ANCA in systemic lupus erythematosus (1993) (2)
FRI0472 Improvements in Joint Outcomes of Psoriatic Arthritis over 4 Years of Treatment with Certolizumab Pegol in Patients with and without Prior Anti-TNF Exposure (2016) (2)
THU0432 Long-Term (104-Week) Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled Trials (2015) (2)
Long-Term Maintenance of Improvements in Multiple Facets of Psoriatic Arthritis With Certolizumab Pegol: 96-Week Patient-Reported Outcome Results Of The Rapid-Psa Study. (2013) (2)
Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors. (2018) (2)
Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations (2022) (2)
SAT0270 5 Year Safety, Efficacy, and Radiographic Data in Patients with Active Psoriatic Arthritis Treated with Golimumab: Long-Term Extension Results of the Randomized, Placebo-Controlled Study Go-Reveal (2013) (2)
Trauma and Inflammatory Arthritis (2013) (2)
The 66/68 Joint Count for the Measurement of MSK Disease Activity/Peripheral Joint Activity in Psa: A Grappa-Omeract Working Group Initiative (2018) (2)
SAT0291 Reduced joint counts misclassify PSA patients with oligoarthritis and miss significant active disease (2013) (2)
Toward Treating to Target in Psoriatic Arthritis (2015) (2)
Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis (2022) (2)
Abstracts of the 5th Congress of the Psoriasis International Network, 7-9 July 2016, Paris. (2016) (1)
THU0299 An integrated analysis of changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis across phase 3 and long-term extension studies (2018) (1)
OP0109 EFFICACY OF FILGOTINIB VS PLACEBO IN ACTIVE PSORIATIC ARTHRITIS: PATIENT-LEVEL DATA FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY (2019) (1)
PMS66 EARLY AND SUSTAINED REMISSION ASSOCIATED WITH NORMALIZED PHYSICAL FUNCTION AND HEALTH-RELATED QUALITY OF LIFE AND SIGNIFICANTLY IMPROVED PRODUCTIVITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH GOLIMUMAB: TWO YEAR DATA FROM THE PHASE III GO-REVEAL CLINICAL TRIAL (2011) (1)
AB0553 BASELINE DISEASE ACTIVITY AS A PREDICTOR FOR ACHIEVING cDAPSA TREATMENT TARGETS WITH APREMILAST IN DMARD-NAIVE PATIENTS WITH MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS (2021) (1)
Adalimumab radiographic efficacy in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use, and clinical response: Subanalysis of ADEPT (2006) (1)
Methodology for clinical trials in rheumatology: logical foundations. (1997) (1)
POS1037 EFFECT OF GUSELKUMAB, A SELECTIVE IL-23p19 INHIBITOR, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PsA: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS (2022) (1)
400 Ana-negative sle: re-evaluation in an international inception cohort (2017) (1)
CE-18 Time to recovery of individual lupus manifestations on standard of care treatment (2016) (1)
BHPR research: qualitative1. Complex reasoning determines patients’ perception of outcome following foot surgery in rheumatoid arhtritis (2012) (1)
CS-03 Hydroxychloroquine in lupus pregnancy: a meta-analysis of individual participant data (2018) (1)
The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial (2022) (1)
SAT0322 The effect of guselkumab on dactylitis: results from a phase 2 study in patients with active psoriatic arthritis (2018) (1)
Gastrointestinal‐related arthritis and psoriatic arthritis (1991) (1)
Psoriatic arthritis--review of current concepts. (1991) (1)
Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study (2017) (1)
Psoriatic arthritis and psoriasis: State of the art review and research advances. Epilogue (2005) (1)
Faculty of 1000 evaluation for Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. (2016) (1)
Reliability of physical examination in inflammatory arthritis: Rope study (2005) (1)
OP0203 CHARACTERIZING THE EPIGENOMIC LANDSCAPE OF PSORIASIS PATIENTS DESTINED TO DEVELOP PSORIATIC ARTHRITIS (2019) (1)
The association of lupus nephritis with adverse pregnancy outcomes among women with lupus in North America (2022) (1)
AB0906 Ixekizumab improves fatigue in a subset of patients with psoriatic arthritis (2018) (1)
Construct Validity of the Swollen and Tender Joint Counts for the Measurement of MSK Disease Activity in Psoriatic Arthritis (2018) (1)
Canadian Rheumatologists’ Perspectives on Moderate Psoriatic Arthritis and Oligoarticular Psoriatic Arthritis (2021) (1)
Discussion: Treatment of psoriatic arthritis and psoriasis (2005) (1)
Incidence, prevalence, and predictors of inflammatory arthritis in patients with hidradenitis suppurativa: a systematic review and meta‐analysis (2021) (1)
Sex Effect in Psoriatic Arthritis (2022) (1)
Response to: ‘Can biomarkers differentiate psoriatic arthritis from osteoarthritis?’ by Tian et al (2019) (1)
Oral and Poster Communications (2016) (1)
Oral abstracts 3: RA Treatment and outcomesO13. Validation of jadas in all subtypes of juvenile idiopathic arthritis in a clinical setting (2012) (1)
SAT0395 RESPONSIVENESS AND CLINICAL TRIAL DISCRIMINATION OF SWOLLEN AND TENDER JOINT COUNTS FOR THE MEASUREMENT OF MSK DISEASE ACTIVITY IN PSORIATIC ARTHRITIS (2019) (1)
HLA associations in patients with pemphigus vulgaris: A Canadian perspective: 976 (2015) (1)
THU0271 PERFORMANCE OF THE EULAR/ACR 2019 CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN EARLY DISEASE, ACROSS SEXES AND ETHNICITIES (2020) (1)
Dr. Eder, et al, reply (2012) (1)
AB0737 MEASUREMENT PROPERTIES OF RADIOGRAPHIC OUTCOME MEASURES IN PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW FROM THE GRAPPA-OMERACT INITIATIVE (2020) (1)
MS4 THE COST-EFFECTIVENESS OF ADDING INFLIXIMAB TO USUAL THERAPY IN THE TREATMENT OF PSORIATIC ARTHRITIS (2005) (1)
Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis (2015) (1)
1116 Long-term ocular safety of hydroxychloroquine in patients with childhood-onset SLE (cSLE) followed into adulthood (2021) (1)
Spondylarthropathies (including psoriatic arthritis) 244. Validity of Colour Doppler and Spectral Doppler Ultrasound of Sacroilicac Joints Againts Physical Examination as Gold Standard (2011) (1)
OP0309 Characterisation of clinical benefits in subjects classified as acr20 non-responders at week 104 of apremilast treatment: subanalysis of 3 long-term, phase iii trials (2018) (1)
ACHIEVING MINIMAL DISEASE ACTIVITY (MDA) CRITERIA DECREASES PROGRESSION OF JOINT DAMAGE IN PSORIATIC ARTHRITIS (2009) (1)
291 Assessment of the QRISK2, QRISK3, SLE cardiovascular risk equation, modified framingham and framingham risk calculators as predictors of cardiovascular disease events in systemic lupus erythematosus (2019) (1)
Disease Development and Outcomes (2016) (1)
Cardiac Magnetic Resonance Imaging and Clinical Follow-up in Antimalarial-induced Cardiomyopathy in Patients With Systemic Lupus Erythematosus (2023) (1)
Predictors of Seizures in Systemic Lupus Erythematosus. (2011) (1)
Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis (2019) (1)
FRI0344 THE LONG-TERM EFFECT OF TREATING PSORIATIC ARTHRITIS WITH THE JANUS KINASE 1-SELECTIVE INHIBITOR FILGOTINIB ON LIPID PROFILES: AN ANALYSIS OF THE EQUATOR AND EQUATOR2 TRIALS (2020) (1)
Trial Adalimumab Effectiveness in Psoriatic Arthritis arthritis: patient-reported outcomes of the functional impairment in patients with psoriatic Adalimumab improves joint-related and skin-related (2007) (1)
patients with psoriatic disease the extent of subclinical atherosclerosis in The Framingham Risk Score underestimates (2013) (1)
Long-Term Improvements in Workplace and Household Productivity and Social Participation Over 4 Years of Certolizumab Pegol Treatment in Patients with Psoriatic Arthritis, with and without Prior Anti-Tnf Exposure (2016) (1)
THU0430 Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis (2016) (1)
Cancer Risk Factors in SLE: Multivariate Regression Analysis in 16,409 Patients (2014) (1)
The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial (2022) (1)
Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials (2021) (1)
Prologue: 2019 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2020) (1)
15262 Cardio-metabolic effects of long-term treatment with secukinumab in psoriatic arthritis and ankylosing spondylitis patients: Pooled 3 year analysis (2020) (1)
Psoriasis assessment tools in clinical trials. Discussion (2005) (1)
25851 Efficacy of secukinumab in managing axial manifestations and nail psoriasis in patients with psoriatic arthritis: Results from the MAXIMISE trial (2021) (1)
OP0224 FILGOTINIB TREATMENT LEADS TO RAPID AND SUSTAINED REDUCTIONS IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS (2020) (1)
OP0223 Abatacept in the treatment of active psoriatic arthritis: 1-year results from a phase iii study (2017) (1)
Erratum: The Systemic Lupus International Collaborating Clinics (SLICC) Group-It Was 20 Years Ago Today (Lupus (2011) 20 (1426-1432) DOI: 10.1177/0961203311421501) (2012) (1)
194 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104 Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III Randomized Controlled Trials (2016) (1)
Outcome measures in psoriatic arthritis. (2005) (1)
FRI0450 PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY OR REMISSION IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH APREMILAST (2019) (1)
SP0154 Comorbidities of Psoriatic Arthritis and Other Rheumatic Diseases (2016) (1)
AB0753 COMPARING COMPOSITE MEASURES OF DISEASE ACTIVITY IN PSORIATIC ARTHRITIS: RESULTS FROM A RANDOMIZED PHASE 2 TRIAL WITH GUSELKUMAB (2019) (1)
FRI0401 EFFECT OF LONG-TERM TREATMENT WITH SECUKINUMAB ON LIPID PROFILE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS: POOLED 4 YEAR ANALYSIS (2019) (1)
Historical Perspectives on Psoriatic Arthritis (2016) (1)
POS0005 BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS (2022) (1)
SAT0373 EFFECT OF FILGOTINIB ON PATIENT-REPORTED OUTCOMES IN ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY (2019) (1)
Characterization of Clinical Benefits in Subjects Classified As ACR20 Non-Responders at Week 104 of Apremilast Treatment: Subanalysis of 3 Long-Term, Phase III Trials (2017) (1)
Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 (2022) (1)
Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 (2022) (1)
Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol. (2015) (1)
Correction: Association of Variants at 1q32 and STAT3 with Ankylosing Spondylitis Suggests Genetic Overlap with Crohn's Disease (2011) (1)
140 Effect of lupus nephritis on pregnancy outcomes in systemic lupus erythematosus: an individual participant meta-analysis (2019) (1)
Making a diagnosis of psoriatic arthritis (2014) (1)
Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials (2022) (1)
POS1045 Ixekizumab efficacy on spinal pain, disease activity and quality of life in patients with psoriatic arthritis presenting with symptoms suggestive of axial involvement (2021) (1)
Exploring cannabis use and perspectives among psoriatic disease patients (2022) (1)
The new EULAR/ACR 2019 SLE classification criteria: A predictor of long-term outcomes. (2022) (1)
A198 LEFLUNOMIDE-INDUCED COLITIS IN IMMUNOSUPPRESSED PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS (2021) (1)
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib (2022) (1)
HLA-Class I genes are associated with a higher burden of atherosclerosis in patients with psoriatic disease (2015) (1)
UGT2B17 copy number gain in a large ankylosing spondylitis multiplex family (2013) (1)
Erratum: Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort (2016) (1)
From ankylosis to pencil-in-cup deformity in psoriatic arthritis: a case report. (2009) (1)
SAT0463 Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years: long-term data from the future 1 and future 2 studies (2017) (1)
Killer cell immunoglobulin‐like receptor gene's repertoire in rheumatoid arthritis (2007) (1)
FRI0522 The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis (2017) (1)
AB0794 Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis: results from two phase 3 studies (2017) (1)
Assessing lupus. (1998) (1)
Lymphoma risk in systemic lupus: effects of treatment versus disease activity (2012) (1)
AB0785 Consistent safety profile with up to 4 years of apremilast treatment: analysis of data from 1493 patients with psoriatic arthritis in 3 large, phase iii, long-term studies (2017) (1)
Lung cancer in systemic lupus erythematosus (2012) (1)
SAT0451 Disease course patterns in systemic lupus erythematosus (2018) (1)
SAT0448 Apremilast treatment and long-term (up to 156 weeks) improvements in dactylitis and enthesitis in patients with psoriatic arthritis: analysis of a large database of the phase iii clinical development program (2017) (1)
AB0921 Impact of baseline demographics, disease activity and concomitant medication on american college of rheumatology 20 response rate and health assessment questionnaire-disability index score with tofacitinib in active psoriatic arthritis: a pooled subgroup analysis of 2 phase 3 studies (2018) (1)
Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics (SLICC) Cohort using Multistate Modelling. (2023) (0)
Yet another linkage reported--what does it mean? (2000) (0)
Anti-Tumor Necrosis Factor-Differential Response of Psoriatic Onycho-Pachydermo-Periostitis to 2 (2008) (0)
SAT0570 Joint Damage is Not Associated with Smoking Status in Patients with Psoriatic Arthritis (2015) (0)
Adalimumab is efficacious in treating skin disease of psoriatic arthritis patients with mild-to-severe baseline skin involvement: Subanalysis of ADEPT (2007) (0)
Sustained improvement in clinical measures of psoriatic arthritis in infliximab-treated patients: 1 year results from impact 2 (2006) (0)
193 Integrating health records and genetic signatures to enhance psoriatic arthritis risk assessment (2017) (0)
THU0417 Improvements in Extra-Articular Manifestations of Psoriatic Arthritis Over 96 Weeks of Certolizumab Pegol Treatment (2015) (0)
Corrigendum to "Psoriatic arthritis disease activity during pregnancy and the first-year postpartum" [Semin. Arthritis Rheum. 46 (6) (2017) 740-745]. (2019) (0)
AB0529 CHARACTERIZATION OF REMISSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB: POST-HOC ANALYSIS FROM TWO PHASE 3 TRIALS (2021) (0)
Sustained Improvements in Productivity at Paid Work and Within Household, and Increased Participation in Daily Activities Over Time with Certolizumab Pegol in Patients with Psoriatic Arthritis: 48-Week Results from the Rapid-PsA Study (2013) (0)
O26 Incidence and predictors of atherosclerotic vascular events in a multicentre inception SLE cohort (2020) (0)
articleVariability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus : a longitudinal cohort study (2015) (0)
C URRENT OPINION What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis (2015) (0)
Correspondence on "relationship between the EULAR/ACR classification criteria and organ damage in systemic lupus erythematosus" by Chi Chiu Mok et al. (2023) (0)
Prevalence of Direct Coombs Test in Systemic Lupus Erythematosus. Clinical and Immunologic Associations (2011) (0)
Faculty Opinions recommendation of A validation study of the Simple Psoriatic Arthritis Screening (SiPAS) questionnaire to screen psoriasis patients for psoriatic arthritis. (2019) (0)
version of SELENA comparison of BILAG 2004 and the flare with systemic lupus erythematosus : a An assessment of disease flare in patients (0)
1124 Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach (2021) (0)
Cancer risk factors in systemic lupus erythematosus: multivariate regression analysis in 16,409 patients (2014) (0)
Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) Related Remission: 2-Year Results from a Phase 3 Study (2018) (0)
FRI0353 Association of Attitudes Toward Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs and Tumor Necrosis Factor Inhibitors and Treatment Adherence in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: Results from the Global Align Study (2015) (0)
Assessment of disease activity and damage in psoriatic arthritis (2014) (0)
Persistence of Biologics in the Treatment of Psoriatic Arthritis (Psa): Data From a Large Hospital Based Longitudinal Cohort. (2023) (0)
CE-21 The prevalence and determinants of ANTI-DFS70 antibodies in an international inception cohort of systemic lupus erythematosus (SLE) patients (2016) (0)
Faculty Opinions recommendation of Development of a preliminary composite disease activity index in psoriatic arthritis. (2011) (0)
OP0252 NEUROPATHIES IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM AN INTERNATIONAL, INCEPTION COHORT STUDY (2019) (0)
THU0616 Treatment Adherence and Attitudes towards Systemic Medications in Patients with Rheumatoid Arthritis in Different Geographical Regions (2016) (0)
219 Effect of complete or partial proteinuria recovery compared to no recovery at 2 years after the diagnosis of lupus nephritis on long term outcomes (2017) (0)
AB0894 Efficacy and Safety of Guselkumab in Biologic-Naïve Patients With Active Axial Psoriatic Arthritis: Study Design of a Phase 4, Randomized, Double-Blind, Placebo-Controlled Trial (2022) (0)
Faculty Opinions recommendation of Higher Incidence Rates of Comorbidities in Patients with Psoriatic Arthritis Compared with the General Population Using U.S. Administrative Claims Data. (2019) (0)
FRI0508 The effect of certolizumab pegol on extra-articular manifestations of psoriatic arthritis over 4 years of treatment in patients with and without prior anti-tnf exposure (2017) (0)
POS0406 miRNAs DEREGULATED IN RESPONSE TO IL17A INHIBITORS IN PSORIATIC ARTHRITIS REGULATE GENE PRODUCTS IN Rho-GTPase PATHWAYS (2021) (0)
Cancer in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort (2017) (0)
Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). (2022) (0)
THU0294 5-year efficacy and safety of apremilast treatment in subjects with psoriatic arthritis: pooled analysis of the palace studies (2018) (0)
Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors (2022) (0)
AB0557 ACHIEVING TREATMENT TARGETS IN PSORIATIC ARTHRITIS WITH APREMILAST IN CANADIAN PRACTICE: REAL WORLD RESULTS FROM APPRAISE (2021) (0)
THU0031 FILGOTINIB TREATMENT PROVIDES RAPID AND SUSTAINED REDUCTION OF INFLAMMATORY BIOMARKERS IN MODERATE TO SEVERE PSORIATIC ARTHRITIS (PSA) PATIENTS (2019) (0)
Faculty Opinions recommendation of Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials. (2021) (0)
Systemic Lupus Erythematosus Risk Factors for Development of Coronary Artery Disease in Women with NIKPOUR and DAFNA (2009) (0)
Diagnostic and classification criteria (2014) (0)
FRI0358 ROLE OF MIRNA-21-5PAS A POTENTIAL BIOMARKER FOR THE INFLAMMATION PATHWAY IN PSORIATIC DISEASE AND RESPONSE TO METHOTREXATE TREATMENT (2019) (0)
P219 Long-term safety of filgotinib in patients with PsA: week 52 safety data from a Phase 2 open-label extension study (2020) (0)
New Data Showcasing Lilly's Growing Commitment in Rheumatology to be Featured at the ACR/ARHP Annual Meeting (2018) (0)
Immunogenetics of rheumatoid arthritis ra hla d antigens in patients with mild disease and with severe disease (1990) (0)
POS1049 EFFECT OF FILGOTINIB ON PASDAS: DRIVERS OF LOW AND VERY LOW ACTIVITY UP TO WEEK 100 (2021) (0)
Abstract6.1-09 HLA typing in cystic fibrosis arthritis and hypertrophic osteoarthropathy (1989) (0)
AB0881 Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2 (2022) (0)
The performance of three anti-dsDNA immunoassays and their correlation with disease activity in systemic lupus erythematosus patients (2011) (0)
154-P: Activating KIRs in siblings of patients with psoriatic arthritis (2009) (0)
from the GRAPPA 2016 Annual Meeting The QUANTUM Report : A Report − − Benchmarking Care in Psoriatic Arthritis (2017) (0)
84-P: Unusual KIR haplotypes in patients with psoriatic arthritis and their family members (2007) (0)
BSR AND BHPR ORAL PRESENTATION OF ABSTRACTS ORAL ABSTRACTS 1: SPONDYLOARTHROPATHIES (2012) (0)
485 Genetic signature to assess risk of psoriasis subtypes through machine learning approach (2017) (0)
SAT0321 Ixekizumab treatment significantly improves enthesitis and dactylitis in patients with active psoriatic arthritis: results from the spirit trials (2018) (0)
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. (2021) (0)
Is Overall Improvement SLEDAI-2K Does Not Conceal Worsening in a Particular System When There (2015) (0)
Erythematosus Disease Activity Index 2000 Responder Index-50 Website Development and Assessment of Users' Satisfaction with the Systemic Lupus (2014) (0)
Economic Evaluation of Damage Accrual in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort (2017) (0)
OP0128 The phenotype of axial psoriatic arthritis: is it dependent on hla-b27 status? (2018) (0)
Team approach to the management of psoriatic arthritis (2014) (0)
Correction: Association of Variants at 1q32 and STAT3 with Ankylosing Spondylitis Suggests Genetic Overlap with Crohn's Disease (2011) (0)
POS1044 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB ON ACR CORE COMPONENTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE EXCEED STUDY (2021) (0)
SAT0276 Improvements in Productivity at Paid Work and Within Household, and Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol in Patients with Psoriatic Arthritis: Results of Rapid-PSA Study (2013) (0)
of Methotrexate in Psoriatic Arthritis Folate Pathway Enzyme Gene Polymorphisms and the Efficacy and Toxicity (2010) (0)
Outcome Measures in Psoriatic Disease (2013) (0)
Skin and nail disease (2014) (0)
POS1050 SECUKINUMAB LEADS TO IMPROVEMENT ACROSS PSORIATIC ARTHRITIS MANIFESTATIONS OVER 2 YEARS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR: A POST HOC ANALYSIS OF FUTURE 5 (2021) (0)
Faculty of 1000 evaluation for Natural history, prognosis, and socioeconomic aspects of psoriatic arthritis. (2016) (0)
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study (2023) (0)
AB0888 Guselkumab Provides Sustained Improvements in Work Productivity and Daily Activity in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2 (2022) (0)
Successive unfolding of two different collagen vascular diseases in the same patient. (1989) (0)
GRAPPA at the European League Against Rheumatism (EULAR) 2008 (2009) (0)
169 Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies (2018) (0)
• Spondyloarthropathies: Current Concepts in Pathogenesis, and the Interplay of Genetics and Infection (2004) (0)
Improving measures of disease activity in systemic lupus erythematosus (2022) (0)
OP0305 RHO-GTPASE PATHWAYS MAY DIFFERENTIATE RESPONDER AND NON-RESPONDERS TO TUMOUR NECROSIS FACTOR INHIBITOR (TNFI) AND INTERLEUKIN-17A INHIBITOR (IL-17AI) THERAPY IN PSORIATIC ARTHRITIS (PSA) (2020) (0)
Erratum: A reliability study of SLEDAI: A disease activity index for SLE (J Rheumatol (1993) 20 (657-660)) (1993) (0)
Faculty Opinions recommendation of Histological evaluation of the relationships between distal interphalangeal psoriatic arthritis and nail psoriasis: correlations with anatomical studies of the normal nail unit and the main radiological data concerning distal interphalangeal psoriatic arthritis. (2020) (0)
FRI0489 Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the rapid-psa study (2017) (0)
Breast, Ovarian and Endometrial Cancers in Women Diagnosed with SLE before Age 40 (2015) (0)
Evaluating the Threshold Score for Classification of Systemic Lupus Erythematosus Using the EULAR/ACR Criteria (2022) (0)
Real-World Retention and Clinical Effectiveness of Secukinumab for Psoriatic Arthritis: Results From the Canadian Spondyloarthritis Research Network (2022) (0)
SAT0462 Secukinumab provides sustained pasdas related low disease activity in psoriatic arthritis: 2 year results from the future 2 study (2017) (0)
Osteonecrosis in Systemic Lupus Erythematosus: Prevalence, Patterns and Outcomes (2015) (0)
Durability of Apremilast Response in Patients With Psoriatic Arthritis: Long-term (208-Week) Results From the PALACE 1 Trial. Société Française de Rhumatologie (SFR) Annual Meeting, Paris, France, Dec 2017. (2017) (0)
The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus (2015) (0)
Clinical and laboratory features of musculoskeletal manifestations (2014) (0)
FRI0356 DIFFERENTIAL EXPRESSION OF HUMAN ENDOGENOUS RETROVIRUSES IN PSORIATIC DISEASE (2019) (0)
SAT0350 Content and face validity and feasibility of five candidate instruments for psoriatic arthritis randomised controlled trials: results from the psa omeract core set workshop at the grappa 2017 annual meeting (2018) (0)
Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension (2023) (0)
Gender-related differences in patients with psoriatic (2012) (0)
10 Performance of SLEDAI-2K Responder Index-50 in a Randomized Placebo-Controlled Trial with Ustekinumab (UST) in Systemic Lupus Erythematosus (2019) (0)
IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING ADALIMUMAB, IMPROVEMENT IN PSORIASIS IS ASSOCIATED WITH LONG-TERM INHIBITION OF RADIOGRAPHIC PROGRESSION (2009) (0)
240-P: Killer cell immunoglobulin-like receptor gene expression in inflamed joints of patients with psoriatic arthritis (PsA) (2009) (0)
Oral abstracts 1: SpondyloarthropathiesO1. Detecting axial spondyloarthritis amongst primary care back pain referrals (2012) (0)
Based on Data from 3 Anti-Tumor Necrosis Factor Randomized Studies Informing Response Criteria for Psoriatic Arthritis . I : Discrimination Models (2010) (0)
FRI0165 The Molecular Convergence of Non-Hla Ankylosing Spondylitis Risk Genes with Autoimmune Diseases (2014) (0)
Faculty Opinions recommendation of Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. (2012) (0)
SAT0288 Male Gender is Associated with Accelerated Radiographic Progression in Axial Damage but not with Progression of Peripheral Damage (2013) (0)
SAT0369 SECUKINUMAB IMPROVES GRAPPA-OMERACT CORE DOMAINS OF PSORIATIC ARTHRITIS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR (2019) (0)
[Prognosis in systemic lupus erythematosus]. (1995) (0)
So You Suspect Mixed Connective Tissue Disease (MCTD) (1984) (0)
OP0111 A RANDOMIZED, PHASE 3, DOUBLE-BLIND TRIAL EXAMINING METHOTREXATE AND ETANERCEPT AS MONOTHERAPY OR IN COMBINATION FOR TREATING PSORIATIC ARTHRITIS: A COMPARISON OF THE COMPOSITE MEASURES USED TO EVALUATE DISEASE ACTIVITY (2019) (0)
Introduction (2018) (0)
Complications The Effect of Lupus Nephritis on Pregnancy Outcome and Fetal and Maternal (2010) (0)
CS-14 Prolonged antimalarial treatment is associated with increased risk for elevated myocardial biomarkers in systemic lupus erythematosus (2018) (0)
1-1-2018 Classification and Outcome Measures for Psoriatic Arthritis (2018) (0)
The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. (2022) (0)
AB0946 Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomised, controlled study in biologic-naÏve subjects with active psoriatic arthritis (2018) (0)
POS0405 GENETIC VARIANTS WITHIN PSORIATIC ARTHRITIS (PsA)-WEIGHTED GENES FBXL19 AND HLA-B*39 MAY SERVE AS A POTENTIAL LINK BETWEEN PsA AND OBESITY (2021) (0)
Disease development and outcome (2021) (0)
260 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis (2019) (0)
Faculty Opinions recommendation of MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage. (2009) (0)
Chapter 6 – Management of Psoriatic Arthritis (2010) (0)
COMMENT Spondyloarthropathies Dafna (2005) (0)
Osteonecrosis in Systemic Lupus Erythematosus: Predictive Factors (2015) (0)
Brain scandiagnosis ofcentral nervoussystem involvement insystemic lupus erythematosus (1978) (0)
Amended 95% Confidence Intervals in Tables in the Article by Jani et al (Arthritis Rheumatol, August 2015) (2015) (0)
Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients (2018) (0)
FRI0429 NON TOPICAL PHARMACOLOGICAL TREATMENT OF EARLY, UNTREATED (DMARD-NAïVE, SYSTEMIC THERAPY-NäIVE) PSORIATIC DISEASE: A SYSTEMATIC REVIEW (2019) (0)
Faculty of 1000 evaluation for Biomarkers in psoriatic arthritis: recent progress. (2016) (0)
Spondyloarthropathies (Including Psoriatic Arthritis) [40–69] 40. Eagle's Syndrome: An Unusual Association with Sero-Negative Arthropathy (2010) (0)
Assessment of the Toronto Psoriatic Arthritis Screen 2 as a Screening Tool for Psoriasis (2021) (0)
Lupus Erythematosus Cell Compartment of Patients with Systemic Antigen-Engaged Cells within the Naive B Expanded Population of Activated Gladman (2007) (0)
603 Remission and low disease activity are associated with lower health care costs in an international inception cohort of patients with systemic lupus erythematosus (2022) (0)
AB0763 SAFETY OF ABATACEPT TREATMENT OVER 2 YEARS IN A PHASE III ACTIVE PSORIATIC ARTHRITIS RANDOMIZED TRIAL (ASTRAEA) (2019) (0)
Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study. (2014) (0)
Author Correction: Evolving concepts in systemic lupus erythematosus damage assessment (2021) (0)
Anti-C1q Antibody in Systemic Lupus Erythematosus (2011) (0)
Faculty Opinions recommendation of Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. (2010) (0)
Alefacept in combination with methotrexate for treatment of active psoriatic arthritis: rationale and design of a randomized, double-blind, placebo-controlled study (2004) (0)
1704 Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes (2021) (0)
Peripheral vascular disease inpatients withsystemic lupuserythematosus (1992) (0)
Dr. Cauli, et al reply (2012) (0)
Faculty Opinions recommendation of Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. (2012) (0)
Imaging in psoriatic arthritis (2014) (0)
Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor (2017) (0)
POS1051 SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND INHIBITS STRUCTURAL DAMAGE IN PsA PATIENTS WITH SUSTAINED REMISSION OR LOW DISEASE ACTIVITY: RESULTS FROM A PHASE 3 STUDY (2021) (0)
Canada treatment recommendations for the management of spondyloarthritis : a The Canadian Rheumatology Association / Spondyloarthritis Research Consortium (2007) (0)
24-Week efficacy and safety results from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT) (2005) (0)
SAT0360 REMISSION IN PSORIATIC ARTHRITIS: DEFINITION AND PREDICTORS (2019) (0)
CE-25 From childhood to adulthood: longitudinal trajectory of damage in patients with childhood-onset systemic lupus erythematosus (CSLE) (2016) (0)
Aetiology and pathogenesis (2014) (0)
The Genetic Basis of Spondyloarthritis: SPARTAN/IGAS 2009 (2011) (0)
Faculty Opinions recommendation of Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. (2007) (0)
Investigation into the wait time for consultation in the psoriatic arthritis program (2022) (0)
CE-26 From childhood to adulthood: identifying latent classes of disease activity trajectories in childhood-onset systemic lupus erythematosus patients (2016) (0)
Isolated Neutropenia in Systemic Lupus Erythematosus (2022) (0)
102 M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort (2022) (0)
Arthritis from Psoriasis Alone and Healthy Controls ? Is the Madrid Sonographic Enthesitis Index Useful for Differentiating Psoriatic (0)
The association of endoplasmic reticulum aminopeptidase 2 (ERAP2) with ankylosing spondylitis (AS) was recently described in the large International Genetics of AS Consortium (2015) (0)
SAT0324 Certolizumab pegol provides sustained remission and minimal disease activity in patients with psoriatic arthritis over 4 years’ treatment (2018) (0)
GRAPPA Historical Perspective (2016) (0)
Disease Activity Index 2000 Responder Index 50 Development and Initial Validation of the Systemic Lupus Erythematosus (2011) (0)
1107 Economic evaluation of hydroxychloroquine use in an international inception cohort (2021) (0)
Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus. (2023) (0)
POS1080 CHARACTERIZATION OF JOINT DISTRIBUTION AND DISEASE BURDEN IN PATIENTS WITH EARLY OLIGOARTICULAR PSORIATIC ARTHRITIS: RESULTS FROM THE ONGOING FOREMOST STUDY (2022) (0)
Reply (2010) (0)
Cardiac Magnetic Resonance Imaging T1 and T2 Mapping in Systemic Lupus Erythematosus in Relation to Antimalarial Treatment (2023) (0)
THU0688 ASSESSMENT OF THE QRISK2, QRISK3, SLE CARDIOVASCULAR RISK EQUATION, FRAMINGHAM AND MODIFIED FRAMINGHAM RISK CALCULATORS AS PREDICTORS OF CARDIOVASCULAR DISEASE EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS (2019) (0)
Faculty Opinions recommendation of Current concepts in psoriatic arthritis: pathogenesis and management. (2016) (0)
SAT0266 Obesity is Associated with Lower Probability of Achieving Sustained Minimal Disease Activity State Among Patients with Psoriatic Arthritis (2013) (0)
PSORIATIC ARTHRITIS PRECIPITATED BY PHYSICAL TRAUMA. REPLY (1991) (0)
POS1037 CORRELATION BETWEEN SKIN INVOLVEMENT, JOINT INVOLVEMENT AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POST-HOC ANALYSIS OF EQUATOR/EQUATOR2 (2021) (0)
International Classification of Functioning , Disability and Health Effect of Psoriatic Arthritis According to the Affected Categories of the (2010) (0)
Recent progress in psoriatic arthritis and areas for further research (2018) (0)
Psoriatic Arthritis and Killer Ig-Like Receptor Combinations in Protection / Susceptibility Conferred by HLA Autoimmune Disease : Hierarchy of Cutting Edge : Heterozygote Advantage in (2004) (0)
SAT0436 Durability of apremilast response in patients with psoriatic arthritis: long-term (208-week) results from the palace 1 trial (2017) (0)
HLA-C Alleles Genes in the Absence of Specific Receptor Killer Ig-Like Arthritis : Influence of Activating Cutting Edge : Susceptibility to Psoriatic (2002) (0)
Durability of apremilast response through 5 years of treatment in subjects with psoriatic arthritis (2018) (0)
Correction to: Psoriasis in systemic lupus erythematosus: a single-center experience (2018) (0)
Incorrect Values for Intractable and Cluster Headaches at Enrollment Shown in Figure 1 and Incorrect Prevalence of Headache at Ten Years in Text of the Article by Hanly et al (Arthritis Rheum, November 2013) (2014) (0)
Reply (2010) (0)
Faculty Opinions recommendation of Psoriatic arthritis screening: a systematic review and meta-analysis. (2019) (0)
DOES EARLY AND AGGRESSIVE TREATMENT IMPROVE THE PROGNOSIS IN PSORIATIC ARTHRITIS? COMMENT ON. AUTHORS' REPLY (1999) (0)
THU0006 Validation of Differential Methylation in Maternally Versus Paternally Transmitted Psoriatic Disease (2015) (0)
Faculty Opinions recommendation of Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. (2016) (0)
Response to: Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE” by Whittall Garcia et al (2021) (0)
Faculty Opinions recommendation of The prevalence of psoriatic arthritis in people with psoriasis. (2009) (0)
166 Long-term (156-week) improvements in dactylitis and enthesitis with apremilast inpsoriatic arthritis subjects: analysis of a large, pooled PALACE 1-3 database (2018) (0)
Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept (2007) (0)
176 Accrual of disease comorbidities over 8 years in a multicentre inception sle cohort (2017) (0)
AB0786 Systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: a grappa-omeract initiative (2017) (0)
AB0929 Is there a correlation between skin severity and joint activity in Psoriatic Arthritis (PsA)? (2022) (0)
Effects of a web based decision aid on parental attitudes to MMR vaccination : a before and after study (0)
Clinical characteristics of psoriatic arthritis and axSpA patients with uveitis (2023) (0)
AB0794 CLINICAL TRIAL DISCRIMINATION OF PHYSICAL FUNCTION INSTRUMENTS FOR PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW (2020) (0)
FRAMINGHAM AND FRAMINGHAM RISK CALCULATORS AS PREDICTORS OF CARDIOVASCULAR DISEASE EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS (2021) (0)
INTERNAL MEDICINE AND PSORIASIS P 001 Risk of self-harm and non-fatal suicide attempts , and completed suicide in patients with psoriasis – a population-based cohort study (2016) (0)
Anti-beta2 Glycoprotein I IgA in Systemic Lupus Erythematosus Versus Controls (2011) (0)
56 Self-reported indirect costs are underestimated in a canadian cohort of patients with SLE (2019) (0)
OP0140 IMPACT OF TIME TO REMISSION, FLARES AND TIME ON IMMUNOSUPPRESSIVES ON THE ESTIMATED GLOMERULAR FILTRATION RATE IN LUPUS NEPHRITIS (2022) (0)
Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes (2023) (0)
HLA-DR4 subtypes in Psoriatic Arthritis (PsA) (1992) (0)
Long-term outcome in pediatric systemic lupus erythematosus (1994) (0)
SAT0481 The relationship between the patient acceptable symptom state (PASS) and disease activity in patients with psoriatic arthritis (PSA) (2017) (0)
Epilogue (2005) (0)
PS4:80 Hydroxychloroquine in lupus pregnancy: a meta-analysis of individual participant data (2018) (0)
Gender-related differences in patients with psoriatic arthritis part of (2012) (0)
177 Association between chronic antimalarial therapy and elevated myocardial biomarkers in patients with systemic lupus erythematosus and no prior heart disease: a preliminary report (2017) (0)
SAT0386 What is the Best Screening Test to Identify Lupus Patients with Cognitive Impairment in an Ambulatory Setting? (2015) (0)
AB0550 EFFICACY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND A LOW OR HIGH SWOLLEN JOINT COUNT: A SUBGROUP ANALYSIS OF 2 PHASE 3 STUDIES (SELECT-PsA 1 AND SELECT-PsA 2) (2021) (0)
The Journal of Rheumatology Sleep Disturbance in Psoriatic Disease: Prevalence and Associated Factors (2017) (0)
FRI0352 PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY OR REMISSION WITH APREMILAST TREATMENT AMONG DMARD-NAIVE SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS (2020) (0)
OP0063 From Childhood to Adulthood: Longitudinal Trajectory of Damage in Patients with Childhood-Onset Systemic Lupus Erythematosus (CSLE) (2015) (0)
THU0424 Treatment with Tnf Alpha Blockers Is Associated with Reduced Progression of Atherosclerotic Plaques in Patients with Psoriatic Disease – A Prospective Study (2016) (0)
OP0095 Customized CNV microarray identified UGT2B17 as a novel susceptibility gene associated with familial ankylosing spondylitis (2013) (0)
CE-22 Cancer in systemic lupus erythematosus: results from the slicc inception cohort (2016) (0)
FRI0440 THE EFFECT OF GUSELKUMAB ON PASDAS, GRACE INDEX, MCPDAI, AND DAPSA: RESULTS FROM A PHASE 2 STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (2019) (0)
IL-1 gene family members are associated with ankylosing spondylitis in both Caucasian and Asian populations: a meta-analysis (2006) (0)
CS-07 Economic evaluation of damage accrual in an international SLE inception cohort (2018) (0)
Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). (2021) (0)
Systemic lupus erythematosus: an update on current pharmacotherapy and future (2013) (0)
AB0704 Red blood cell but not plasma phospholipids profile may be associated with the presence of carotid plaques in women with systemic lupus erythematosus (2013) (0)
SAT0336 Measurement properties of the minimal disease activity criteria for psoriatic arthritis (2018) (0)
AB0743 Low rates of major adverse cardiac events, malignancies, and serious infections in patients with psoriasis and psoriatic arthritis treated with apremilast for ≥156 weeks: pooled analysis from the esteem and palace 1-3 phase 3 trials (2017) (0)
THU0250 EARLY IMPROVEMENT IN SLEDAI-2K RESPONDER INDEX-50 PREDICTS SRI-4 RESPONSE IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF USTEKINUMAB (UST) IN SYSTEMIC LUPUS ERYTHEMATOSUS (2019) (0)
POS0200 CLINICAL CHARACTERISTICS & OUTCOMES ASSOCIATE WITH WORK PRODUCTIVITY IN BIO-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH WEEK 24 OF THE DISCOVER-2 STUDY (2021) (0)
1501 Genetics of age at systemic lupus erythematosus diagnosis (2021) (0)
Proceedings of the Second Update on Psoriatic Disease, University Federico II Congress Center, July 6–7, 2011, Naples, Italy. (2012) (0)
Psoriatic arthropathy. (1968) (0)
THU0197 Time to recovery from proteinuria in lupus nephritis patients receiving standard of care treatment (2013) (0)
The Journal of Rheumatology Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus (2016) (0)
Necrosis Factor Therapy Neuromuscular Involvement in Rheumatic Patients Treated with Anti-Tumor (2008) (0)
Abstracts of original contributions ASNC 2004 9th annual scientific session September 3-–October 3, 2004 New York, New York (2004) (0)
92-P: KIR haplotypes in psoriatic arthritis families (2007) (0)
Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2021) (0)
Canadian Clinical Practice Setting : The REPArE Trial Effectiveness and Safety of Etanercept in Patients with Psoriatic Arthritis in a (2011) (0)
POS0740 IMPACT OF TIME TO REMISSION, FLARES AND EXPOSURE TO IMMUNOSUPPRESSIVES ON THE DEVELOPMENT OF ADVANCED CHRONIC KIDNEY DISEASE (STAGE IV OR WORSE) IN LUPUS NEPHRITIS (2022) (0)
OP0289 LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON- OR OFF-TREATMENT) PREVENT DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IN A MULTINATIONAL MULTICENTER COHORT (2021) (0)
Infliximab therapy results in sustained improvement in functional status and quality of life in patients with psoriatic arthritis - Results from the IMPACT 2 study. (2005) (0)
746 Challenges and opportunities for integrating genetics and health records in risk assessment for psoriasis subtypes (2018) (0)
Reply (2015) (0)
Improvement in psoriasis is associated with long-term inhibition of radiographic progression in patients with psoriatic arthritis receiving adalimumab (HUMIRA (R)) (2008) (0)
Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. (2021) (0)
AB0895 Residual burden and disease activity of Canadian PsA patients treated with advanced therapies: preliminary results from a multiple registry analysis (UNISON-PsA) (2022) (0)
FRI0477 A Modified Version of The Psoriatic Arthritis Disease Activity Score (MPASDAS) Using Sf-12 as A Measure of Quality of Life May Be More Feasible in Clinical Practice (2016) (0)
SNPs of tumour necrosis factor-α promotor and corneodesmosin genes: Role of susceptibility to and linkage with MHC alleles in psoriatic arthritis (PsA) (2004) (0)
FRI0339 Sledai-2k responder index-50 is effective in demonstrating partial response in a phase 2, randomised placebo-controlled study of ustekinumab in patients with active systemic lupus erythematosus (2018) (0)
S15.2 Severe non-adherence to hydroxychloroquine is associated with flares, early damage, and mortality in systemic lupus erythematosus: data from 660 patients from the slicc inception cohort (2022) (0)
Faculty Opinions recommendation of Development of a Preliminary Ultrasonographic Enthesitis Score in Psoriatic Arthritis - GRAPPA Ultrasound Working Group. (2019) (0)
P124 The impact of the new American college of cardiology/american heart association (ACC/AHA) definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus (2020) (0)
445 Predictors of good long-term renal outcomes (2017) (0)
Effectiveness of Disease-Modifying Antirheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort (2022) (0)
SAT0345 Quality indicators in the care of psoriatic arthritis (2018) (0)
SAT0564 Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol (2015) (0)
Reply (2011) (0)
122 – Management of psoriatic arthritis (2015) (0)
Reply: To PMID 25545846. (2015) (0)
A Paper Patient-Based Flare Study in SLE (2015) (0)
Evaluating enthesitis in patients with pondyloarthritis (SpA) (2006) (0)
263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period (2019) (0)
205 Longitudinal immune changes during and after recent flares in lupus (2022) (0)
two distinct Canadian populations and psoriatic arthritis in SEEK 1 Association of and (2005) (0)
074. LONG-TERM (UP TO 156 WEEKS) SAFETY PROFILE OF ORAL APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF PALACE 1–3 (2017) (0)
The Initial Presentation of Cerebrovascular Disease Attributed to Lupus Is Most Frequent Early in the Disease Course: Results from an International, Inception Cohort Study (2015) (0)
The Journal of Rheumatology Lupus Erythematosus: Results from the SLICC Inception Cohort Osteopontin and Disease Activity in Patients with Recent-onset Systemic (2019) (0)
Outcomes following antimalarial withdrawal in patients with quiescent systemic lupus erythematosus. (2022) (0)
Psoriatic arthritis. (1990) (0)
A Prospective Study of Seizures in Systemic Lupus Erythematosus. (2011) (0)
FRI0395 Sle disease activity index glucocorticoid index (SLEDAI-2KG) identifies more responders than sledai-2k (2018) (0)
AB0383 Measuring partial and complete recovery in active organ systems of lupus patients on standard of care treatment (2013) (0)
SAT0404 Spot Urine Protein/Creatinine Ratio is Useful in Screening for Proteinuria but Should Not Substitute 24 hours Urine Collection Sample to Quantify Proteinuria in Lupus (2015) (0)
11 Development and initial validation of a novel lupus disease activity index to account for glucocorticoids: SLEDAI-2K glucocorticoids index (SGI) (2017) (0)
SAT0308 Responsiveness of Patient Reported Outcomes to Biological Treatment in Psoriatic Arthritis (2013) (0)
Faculty Opinions recommendation of Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study. (2012) (0)
AB0512 Use of Nominal Group Technique To Facilitate Item Reduction for Sle Classification Criteria Development (2016) (0)
SAT0566 Impact of Disease Management by Rheumatologists and Dermatologists on Patients' Attitude Toward Medication in Psoriatic Arthritis: Results from the Global Align Study (2015) (0)
FRI0351 DOES SEX OR BODY MASS INDEX IMPACT RESPONSE TO THERAPY IN PSORIATIC ARTHRITIS?: RESULTS FROM A PHASE 3, DOUBLE-BLIND, RANDOMIZED TRIAL EXAMINING METHOTREXATE AND ETANERCEPT AS MONOTHERAPY OR IN COMBINATION FOR TREATING PSORIATIC ARTHRITIS (2020) (0)
THU0301 A novel role for the psoriatic arthritis impact of disease questionnaire (PSAID) (2018) (0)
1303 The new EULAR/ACR 2019 SLE classification criteria: a predictor of long-term outcomes (2021) (0)
Relationship between myocardial perfusion scinti-graphy and brachial artery endothelial function in systemic lupus erythematosus (2004) (0)
arthritisrecommendations for psoriatic (2010) (0)
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis: results from a randomised, placebo-controlled, phase 2 trial (EQUATOR) (2019) (0)
FRI0447 Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from A Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 1) (2016) (0)
Faculty Opinions recommendation of Biomarkers in psoriatic arthritis: a systematic literature review. (2016) (0)
POS1068 Cardiac biomarkers are associated with the development of cardiovascular events in patients with psoriatic arthritis and psoriasis (2021) (0)
1117 Neutrophil extracellular traps as a biomarker to predict outcomes in lupus nephritis (2022) (0)
POS1038 THE EFFECT OF FILGOTINIB ON ENTHESITIS: 100-WEEK DATA FROM AN OPEN-LABEL EXTENSION STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (2021) (0)
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine (2022) (0)
103 Exploratory segregation of patients upon their levels of anti- mitochondrial antibodies (AMAs) reveals associations between AMAs and disease manifestations (2022) (0)
Faculty Opinions recommendation of PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. (2016) (0)
CE-10 Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort (2016) (0)
Concurrent Oral 6 – Spondylarthropathies [OP40–OP47] OP40. Association of IL23R and IL12B Polymorphisms with Psoriatic Arthritis (2010) (0)
POS1093 EFFECT OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON DEPRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS IN A LONGITUDINAL COHORT (2022) (0)
Correction to: The association between sonographic enthesitis and radiographic damage in psoriatic arthritis (2019) (0)
Dr. Tselios, et al, reply (2019) (0)
Metrics in Disease Activity Measures in Systemic Lupus Erythematosus (2021) (0)
CS-36 Recommendations for the assessment of systemic lupus erythematosus in canada (2018) (0)
THU0421 Serum-Based Soluble Markers May Differentiate Psoriatic Arthritis from Osteoarthritis (2016) (0)
Objectives : To estimate the incidence of PsA in patients with psoriasis and to identify risk factors for its development (2015) (0)
THU0444 Subclinical Ultrasonographic Enthesitis in Patients with Psoriasis Is Associated with Risk Markers for Psoriatic Arthritis (2016) (0)
Faculty Opinions recommendation of The STRIPP questionnaire (Screening Tool for Rheumatologic Investigation in Psoriatic Patients) as a new tool for the diagnosis of early psoriatic arthritis. (2019) (0)
Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network (2023) (0)
Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group. (2022) (0)
OP0030 ASSOCIATION OF TRADITIONAL AND DISEASE-RELATED RISK FACTORS WITH CARDIOVASCULAR EVENTS IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS (2022) (0)
Faculty Opinions recommendation of Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. (2019) (0)
Genetics of Osteonecrosis in Children and Adults with Systemic Lupus Erythematosus. (2023) (0)
801 Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk (2021) (0)
Reply (2017) (0)
POS1028 PATIENT CHARACTERISTICS & CLINICAL FEATURES ASSOCIATE WITH HEALTH-RELATED QUALITY OF LIFE IN BIO-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH WEEK 24 OF THE DISCOVER-2 STUDY (2021) (0)

This paper list is powered by the following services:

Other Resources About Dafna D. Gladman

What Schools Are Affiliated With Dafna D. Gladman?

Dafna D. Gladman is affiliated with the following schools:

University of Toronto

Dafna D. Gladman's Academic­Influence.com Rankings

Why Is Dafna D. Gladman Influential?

Dafna D. Gladman's Published Works

Published Works

Other Resources About Dafna D. Gladman

What Schools Are Affiliated With Dafna D. Gladman?

Dafna D. Gladman's AcademicInfluence.com Rankings